



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Perivascular space in Parkinson's disease: Association with CSF amyloid/tau and cognitive decline

Citation for published version:

Chen, H, Wan, H, Zhang, M, Wardlaw, JM, Feng, T & Wang, Y 2022, 'Perivascular space in Parkinson's disease: Association with CSF amyloid/tau and cognitive decline', *Parkinsonism & Related Disorders*, vol. 95, pp. 70-76. <https://doi.org/10.1016/j.parkreldis.2022.01.002>

Digital Object Identifier (DOI):

[10.1016/j.parkreldis.2022.01.002](https://doi.org/10.1016/j.parkreldis.2022.01.002)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Parkinsonism & Related Disorders

Publisher Rights Statement:

This is the author's peer-reviewed manuscript as accepted for publication.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



[Click here to view linked References](#)

1 **Perivascular Space in Parkinson's disease: Association with CSF Amyloid/Tau and Cognitive**
2
3 **decline**

4
5
6 Huimin Chen^{a,b,c,d}, Huijuan Wan^{b,c,d,e}, Meimei Zhang^{b,c,d}, Joanna M Wardlaw^f, Tao Feng^{b,c,d}, Yilong
7
8
9 Wang^{b,c,d}

10
11 ^aDepartment of Neurology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Medicine, Chinese Academy of Medical Sciences, Beijing, China

^bDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

^cChina National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing, China

^dAdvanced Innovation Center for Human Brain Projection, Capital Medical University, Beijing, China

^eDepartment of Neurology, First Affiliated Hospital, Xiamen University, Xiamen, China

^fCentre for Clinical Brain Sciences, UK Dementia Research Institute, University of Edinburgh,
Edinburgh, UK

Corresponding author:

Yilong Wang*, MD, PhD.

Address: China National Clinical Research Center for Neurological Diseases, Beijing Tiantan

Hospital, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing,

China. 100070.

E-mail: yilong528@gmail.com, Tel: +86-139-1166-6571;

Keywords/Search terms: Parkinson's disease; Perivascular Space; Cognition; Amyloid; Tau

Title: 97 characteristics; Tables: 2; Figures:2; supplementary table 4; supplementary figure 3;

Reference:28;

Word count: abstract 249; body of the manuscript 3262;

1 **Abstract**

2
3 **Objective:** Whether perivascular space (PVS) visible on magnetic resonance imaging (MRI) represents
4
5
6 glymphatic dysfunction and whether this imaging marker is pathologic in Parkinson's disease (PD)
7
8
9 have been controversial. The objective was to determine whether PVS visible on MRI is independently
10
11 associated with cognitive decline in patients with PD, and to test whether pathologic proteins in the
12
13 CSF (such as A β ₄₂) mediate the pathologic role of PVS.
14
15

16 **Methods:** A total of 341 patients with Parkinson's disease from Parkinson's Progression Marker
17
18 Initiative (PPMI) cohort was included in the present study. PVS in the basal ganglia (BG-PVS) and
19
20 centrum semiovale were evaluated with a semiquantitative scale. Changes in the Montreal Cognitive
21
22 Assessment (MoCA) score and the absolute MoCA score at the 3-year assessment were considered the
23
24 main cognitive outcome. A multivariable linear regression model was used to test the association
25
26 between PVS and cognitive decline. A mixed linear model and path analysis were used to test the
27
28 interaction among PVS, CSF biomarkers and cognitive decline.
29
30
31
32
33
34
35

36 **Results:** BG-PVS was associated with cognitive decline in patients with PD at the 3-year follow-up
37
38 independent of age, baseline cognition, motor and nonmotor function, presynaptic dopaminergic
39
40 deficiency, and CSF biomarkers. The interaction between BG-PVS and A β ₄₂/tTau, A β ₄₂/pTau, and A β ₄₂
41
42 levels was significantly predictive of 3-year cognitive decline. Path analysis confirmed that CSF
43
44 A β ₄₂/tTau levels partially mediated the pathologic effect of BG-PVS on cognitive outcome in PD.
45
46
47
48
49

50 **Conclusions:** BG-PVS is independently associated with cognitive decline in PD, and this association
51
52 may be partially mediated by toxic CSF proteins.
53
54

55 **Keywords:** Parkinson's disease; Perivascular Space; Cognition; Amyloid; Tau
56
57
58
59
60
61
62
63
64
65

1
2
3 **1. Introduction**

4 Parkinson's disease (PD) is the second most common neurodegenerative disease, with α -synuclein (α -
5 syn) aggregation and Lewy body deposition being the pathologic hallmarks. Previous studies from
6
7 several cohorts consistently reported that Alzheimer's disease (AD)-related CSF biomarkers (i.e., lower
8
9 levels of $A\beta_{42}$ and $A\beta_{42}/\text{Tau}$ ratios and higher levels of total and phosphorylated Tau) were associated
10
11 with cognitive impairment in PD cross-sectionally [1-3] and longitudinally [4-6].
12
13
14
15
16
17

18 Emerging evidence has highlighted the role of the perivascular space (PVS) as a glymphatic
19
20 pathway for waste clearance in the brain and demonstrated that glymphatic dysfunction reduced
21
22 cerebrospinal fluid (CSF) clearance of $A\beta$ in AD models and in patients with AD [7-9]. Since AD-
23
24 related proteins are toxic to neurons and glial cells [10] and are associated with cognitive decline in AD
25
26 and PD, it is possible that reduced CSF clearance of toxic proteins as a result of glymphatic
27
28 dysfunction may aggregate the neurodegenerative process and facilitate the development of dementia.
29
30
31
32
33
34 A previous cohort from Korea demonstrated that basal-ganglia PVS (BG-PVS) visible on MRI
35
36 predicted cognitive decline in PD at the 5-year follow-up [11]. This result needs to be validated in other
37
38 cohorts. In addition, if BG-PVS visible on MRI reflects glymphatic dysfunction, there might be an
39
40 association between the severity of BG-PVS visible on MRI and higher neurodegenerative burden
41
42
43 measured by CSF biomarkers such as $A\beta$.
44
45
46
47
48

49 The Parkinson's Progression Marker Initiative (PPMI) is the largest ongoing cohort of PD with
50
51 comprehensive clinical, imaging and CSF biomarker data. The PPMI provides an opportunity to
52
53 confirm the pathologic role of BG-PVS in PD cognitive outcome. In addition, it provides superb data to
54
55 test the relationship between PVS visible on MRI and neurodegenerative burden measured by CSF
56
57 biomarkers, which may inform the mechanism and potential therapeutic target of PVS in progressive
58
59
60
61
62
63
64
65

1 neurodegenerative processes.
2
3
4
5

6 **2. Method**

7 **2.1 Study design and participants**

8 PPMI is an ongoing, multicenter, longitudinal, observational study that started in 2010
9
10

11 (<https://www.ppmi-info.org/>). Patients with early, drug-naïve PD and intact cognition were included.
12
13

14 The PPMI study was approved by the institutional review board at each site, and participants provided
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
written informed consent to participate. The protocol and more detailed study design of PPMI has been
described elsewhere [12]. From the whole PPMI cohort, only PD patients with complete baseline BG-
PVS profiles and CSF biomarkers were included in the present analysis. The data used in the current
study were downloaded from the PPMI dataset in June 2020.

31 **2.2 Outcome measurements**

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Cognitive decline was evaluated using the change in the MoCA score from baseline to 3-year follow-
up and the absolute MoCA score at the 3-year assessment. The Hopkins Verbal Learning Test (HVLT)
(memory), the Benton Judgment of Line Orientation 15-item version (visuospatial function), the
Symbol-Digit Modalities Test (processing speed), the Letter Number Sequencing (executive function
and working memory), and the semantic (animal) fluency test (language) were also performed. Motor
function was measured using the Movement Disorder Society Unified Parkinson's Disease Rating
Scale (MDS-UPDRS) part III and Hoehn-Yahr stage. Nonmotor symptoms in the prediction of
cognitive decline in PD included rapid eye movement behavior disorder (RBD), which was assessed
with the RBD Screening Questionnaire (RBDSQ); sense of smell, which was assessed with the
University of Pennsylvania Smell Identification Test (UPSIT); depression, which was assessed with the

1 15-item Geriatric Depression Scale (GDS); and anxiety, which was assessed with the State-Trait
2
3 Anxiety Inventory.
4
5

6 7 **2.3 DAT imaging** 8 9

10 [123I]β-CIT DAT single-photon emission computed tomography (SPECT) imaging was acquired at
11
12 PPMI imaging centers in accordance with the PPMI imaging protocol. Mean caudate and putaminal
13
14 uptake relative to uptake in the occipital area and asymmetry of caudate and putaminal uptake (side
15
16 with highest divided by side with lowest uptake) were computed for the analysis.
17
18
19
20
21

22 **2.4 History of cardio- and cerebrovascular diseases and risk factors** 23 24

25 Histories of cardio- and cerebrovascular diseases were recorded in the PPMI cohort at patient
26
27 screening. Cardiovascular diseases and risk factors include a history of diabetes, hypertension,
28
29 hyperlipidemia, hypercholesterolemia, and cardiac diseases. Cerebrovascular diseases included a
30
31 history of cerebrovascular accident, transient ischemic attack, ischemic stroke, cervical and carotid
32
33 stenosis or occlusion.
34
35
36
37
38
39

40 **2.5 Imaging markers of cerebral small vessel disease** 41 42

43 Imaging markers of cerebral small vessel disease (CSVD) were evaluated by a neurologist who was
44
45 blind to the patient information (HJ Wan) following the instruction and definition of Standards for
46
47 ReportIng Vascular changes on nEuroimaging (STRIVE) [13]. White matter hyperintensity (WMH)
48
49 was rated according to the Fazekas rating scale [14]. Perivascular space was defined on MRI as small,
50
51 sharply delineated structures of CSF intensity (or close to CSF intensity) following the course of
52
53 perforating vessels. PVS in the basal ganglia and centrum semiovale (CS-PVS) were rated separately
54
55 on T2 weighted sequence as 0 = none, 1 = 1–10, 2 = 11–20, 3 = 21–40, and 4 = >40 PVS per side, and
56
57
58
59
60
61
62
63
64
65

1 the worse side was used if there was asymmetry [15, 16]. In the statistical analysis for BG-PVS,
2
3 patients were stratified into groups with moderate-to-severe BG-PVS (BG-PVS rating \geq 2) and none-to-
4
5 mild BG-PVS (BG-PVS rating $<$ 2). Similarly, in the analysis for WMH and CS-PVS, patients were also
6
7 grouped into the high WMH group (Fazekas $>$ 2) versus the low WMH group (Fazekas \leq 2) and the high
8
9 CS-PVS group (CS-PVS rating \geq 2) versus the low CS-PVS group (CS-PVS rating $<$ 2). This
10
11 stratification was consistent with the distribution of CSVD profiles in our data and was consistent with
12
13 studies showing that BG-PVS rating \geq 2 (moderate to severe) was predictive of unfavorable outcomes
14
15
16
17
18
19
20 [15, 16].
21

22 **2.6 Genotyping**

23
24
25 At the screening visit, genomic DNA was extracted from whole blood of the subject. The APOE
26
27 genotype was analyzed at the PPMI genetic core as previously described [17]. Subjects were classified
28
29 by the presence or absence of *APOE* ϵ 4 genotypes.
30
31

32 **2.7 CSF biomarkers**

33
34
35 The concentration of α -synuclein in CSF samples was analyzed using an ELISA assay available
36
37 commercially from BioLegend. CSF A β ₄₂, total tau (tTau) and tau phosphorylated at the threonine 181
38
39 position (pTau) were analyzed at Biorepository Core laboratories to the University of Pennsylvania
40
41 using Elecsys electrochemiluminescence immunoassays (Roche Diagnostics). More detail and primary
42
43 results of the measured CSF biomarkers have been reported previously in the PPMI cohort [17, 18].
44
45
46
47
48
49

50 **2.8 Statistics**

51
52
53 Continuous variables were compared between groups using the Mann-Whitney test (nonnormal
54
55 distribution) or two sample t test (normal distribution), and categorical variables were compared
56
57 between groups using the Chi-square test. Univariate and multivariable linear regression models were
58
59
60
61

1 performed using the MoCA score at the 3-year follow-up and the 3-year change in the MoCA score as
2
3 separate dependent variables. The regression models consulted a previous PPMI study using 2-year
4
5 cognitive outcomes [19]. Variables showing a tendency to significant association ($p < 0.1$) further
6
7 entered the multivariable linear regression analysis simultaneously, while only one significant variable
8
9 of the same feature with lower P value was selected to avoid collinearity. As CSF biomarkers were
10
11 significantly correlated with each other (supplementary figure 1)[20], each biomarker entered the
12
13 multivariable regression model separately.
14
15
16
17
18
19

20 The interaction between BG-PVS and CSF biomarkers in relation to cognition was first explored
21
22 by plotting the fitting curve and then by linear mixed models. The change in MoCA score and MoCA
23
24 score at the 3-year follow-up was used as dependent variables in linear mixed models, BG-PVS
25
26 severity and CSF biomarker with or without interaction term were set as fixed effects, and other
27
28 variables showing significant association with cognitive outcomes in multivariable regression were
29
30 used as random effects. The Akaike information criterion (AIC) of models with and without the BG-
31
32 PVS*CSF biomarker interaction item was recorded. Path analysis was conducted to investigate how
33
34 much CSF biomarkers mediated the effect of BG-PVS on cognition in PD. The standardized coefficient
35
36 (β) of BG-PVS without a mediation effect (direct effect) and with a mediation effect (indirect effect)
37
38 and the standardized coefficient (β) of the CSF biomarker on the change in MoCA were calculated. P
39
40 value < 0.05 was defined as significant. Group comparison of CSF biomarkers at each follow-up point
41
42 was also performed between PD groups with different BG-PVS severities. P value < 0.01 was defined
43
44 as significant in this group comparison for multiple comparison correction (Bonferroni correction for 4
45
46 repeated comparisons). Group comparison was conducted in SPSS 25.0 (SPSS, inc., Beijing, China),
47
48 and linear regression and linear mixed models were performed in R software version 4.02
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 (https://www.r-project.org/).
2

3 To rule out confounding by other CSVD markers and to investigate the location specificity of
4 PVS, the relationship among WMH or CS-PVS, CSF biomarkers, and cognitive decline was further
5 explored using a similar statistical approach.
6
7
8
9

10 **2.9 Data Availability Statement.**

11 The data was publicly available on PPMI website (https://www.ppmi-info.org/access-data-specimens/).
12
13
14
15
16
17
18
19

20 **3. Results**

21 **3.1 Baseline features of the included patients**

22 Four hundred and twenty three patients with drug-naïve PD were recruited in PPMI cohort. Among
23 these subjects, MRI imaging or T2-weighted imaging was missing in 47 patients, and imaging in
24 another 13 patients was not qualified to rate BG-PVS due to incomplete or nonaxial slices. CSF
25 biomarkers were missing in another 22 patients with PD. Finally, 341 patients with complete baseline
26 PVS and CSF biomarkers were included in the present analysis. The included and excluded patients
27 showed overall similar demographic and behavioral profiles (supplementary table 1).
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **3.2 Group comparison between patients with lower and higher BG-PVS burdens**

43 Compared with patients with lower BG-PVS burden, patients with more severe BG-PVS were
44 significantly older; had more impaired motor function at baseline; had a higher prevalence of previous
45 cardiovascular disease and more severe WMH at baseline; had a higher risk of cognitive impairment
46 and a greater decline in the MoCA score at the 3-year follow-up despite of similar baseline MoCA
47 scores; and showed lower levels of CSF α -synuclein, $A\beta_{42}/tTau$, $A\beta_{42}/pTau$ and higher levels of CSF
48 tTau and pTau at baseline (**Table 1**).
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

3.3 Univariate linear regression for cognition at the 3-year follow-up

Using the absolute MoCA score at the 3-year follow-up as the dependent variable, age, baseline MoCA score, MDS-UPDRS III score, RBDSQ, UPSIT score, CSF A β ₄₂, tTau, pTau, A β ₄₂/tTau, A β ₄₂/pTau, putamen asymmetry and BG-PVS were significantly associated with cognition at the 3-year follow-up in PD patients (P<0.05).

Using decline in MoCA score as the dependent variable, age, baseline MoCA score, RBDSQ, UPSIT score, CSF A β ₄₂, tTau, pTau, A β ₄₂/tTau, A β ₄₂/pTau, putamen asymmetry and BG-PVS were significantly associated with cognitive decline during three years in PD patients (P<0.05) (supplementary table 2).

3.4 Multivariable linear regression for cognition at the 3-year follow-up

In multivariable regression models, BG-PVS was significantly associated with MoCA score or change in MoCA score, independent of age, baseline cognition, motor function, nonmotor symptoms, presynaptic dopaminergic deficiency, and CSF biomarkers. Baseline CSF A β ₄₂, A β ₄₂/tTau and A β ₄₂/pTau were significantly associated with the MoCA score or change in the MoCA score at 3-year follow-up independent of age, baseline cognition, motor function, nonmotor symptoms, presynaptic dopaminergic deficiency, and BG-PVS. However, baseline CSF tTau and pTau were not significantly associated with either cognitive outcome at year three after adjustment (supplementary table 3).

3.5 Interaction between CSF biomarkers and BG-PVS

There was a significant main effect of BG-PVS and CSF A β ₄₂/tTau, A β ₄₂/pTau and A β ₄₂ as well as interactions between BG-PVS and these CSF biomarkers (**Table 2**), such that patients with higher BG-PVS and lower A β ₄₂/tTau (**Figure 1A**), A β ₄₂/pTau (**Figure 1B**), or A β ₄₂ (**Figure 1C**) showed steeper decline in the MoCA score at the 3-year follow-up. Models containing interaction terms provided a

1 slightly improved fit. As patients with a higher BG-PVS burden had a higher prevalence of
2
3 cardiovascular disease and risk factors, we further tested whether the interaction between BG-PVS and
4
5 CSF biomarkers was confounded by the presence of cardiovascular disease and risk factors. However,
6
7 the correlation between CSF biomarkers and cognitive decline was not stratified by the presence of
8
9 cardiovascular disease or related risk factors (supplementary figure 2).
10
11
12

13
14 We further compared CSF biomarkers at each follow-up timepoint between the BG-PVS groups.
15
16 The results revealed that patients with more severe BG-PVS showed significantly higher levels of all
17
18 measured CSF biomarkers at baseline, 1-year follow-up, and 2-year follow-up, and the significant
19
20 difference in tTau and pTau was still observed at year three (supplementary table 4) with corrected P
21
22 values ($P < 0.01$).
23
24
25
26

27 **3.6 Path analysis**

28
29 In path analysis, CSF $A\beta_{42}/tTau$ was found to mediate the effect of BG-PVS on cognitive decline (total
30
31 effect [original coefficient] = -0.256, direct effect [corrected coefficient] = -0.208, indirect effect = -
32
33 0.048) (**Figure 2A**). That is, CSF $A\beta_{42}/tTau$ mediated 18.8% (indirect effect/total effect) of the BG-
34
35 PVS effect on the decrease in MoCA scores during the 3-year follow-up. In path analysis, the
36
37 correlation of BG-PVS with $A\beta_{42}/pTau$ was marginally significant, and that with $A\beta_{42}$ was not
38
39 significant (**Figure 2B and 2C**).
40
41
42
43
44
45
46

47 **3.7 Additional analysis with WMH and CS-PVS**

48
49 For WMH, no significant difference in baseline CSF biomarkers (α -syn $z = -1.337$, $P = 0.181$; $A\beta_{42}$ $z =$
50
51 -0.430, $P = 0.667$; pTau $z = -1.181$, $P = 0.238$; tTau $z = -1.697$, $P = 0.090$) was found between groups
52
53
54 with different WMH severity (Fazekas 0-2 vs. Fazekas 3-6). No significant correlation was found
55
56 between CSF biomarkers and WMH Fazekas rating according to the Spearman correlation analysis (α -
57
58
59
60
61
62

1 syn $r = 0.025$, $P = 0.640$; $A\beta_{42}$ $r = -0.057$, $P = 0.300$; pTau $r = 0.036$, $P = 0.534$; tTau $r = 0.039$, $P =$
2
3 0.331). No significant correlation was observed between WMH and cognitive decline or between
4
5
6 WMH and CSF biomarkers ($A\beta_{42}/tTau$, $A\beta_{42}/pTau$, $A\beta_{42}$) in the path analysis (supplementary figure 3).
7

8
9 For CS-PVS, no significant difference in baseline CSF biomarkers (α -syn $z = -1.391$, $P = 0.164$;
10
11 $A\beta_{42}$ $z = -0.685$, $P = 0.493$; pTau $z = -1.422$, $P = 0.155$; tTau $z = -1.741$, $P = 0.082$) was found between
12
13 groups stratified by CS-PVS severity (CS-PVS 0-1 vs. CS-PVS ≥ 2). No significant correlation was
14
15 observed between CS-PVS and CSF biomarkers ($A\beta_{42}/tTau$, $A\beta_{42}/pTau$, $A\beta_{42}$) in path analysis
16
17 (supplementary figure 3). Although a marginally significant correlation between CS-PVS and cognitive
18
19 decline was observed in the path analysis, the significant correlation was not preserved in the
20
21 multivariable linear model adjusting for age (coefficient = -0.729 , 95% CI = -1.612 – 0.154 , $P = 0.105$)
22
23 or in the model adjusted for age, baseline MoCA scores, baseline state trait anxiety score, RBDSQ,
24
25 UPSIT, and putamen asymmetry (coefficient = -0.615 , 95% CI = -1.419 – 0.188 , $P = 0.132$).
26
27
28
29
30
31
32
33
34
35

36 **4. Discussion**

37
38
39 This is the first study that examined the relationship between CSF biomarkers and PVS visible on MRI
40
41 in neurodegenerative disease. The main finding demonstrated that BG-PVS was independently
42
43 associated with cognitive decline in patients with PD. In addition, BG-PVS modified the pathologic
44
45 effect of $A\beta_{42}/tTau$, $A\beta_{42}/pTau$, and $A\beta_{42}$ on cognitive decline in PD. Path analysis confirmed that CSF
46
47 biomarkers, especially $A\beta_{42}/tTau$, partially mediated the pathologic effect of BG-PVS on cognitive
48
49 outcomes in PD. These results suggest that the increased visibility of BG-PVS on MRI may reflect
50
51 more advanced glymphatic dysfunction, resulting in higher levels of toxic CSF proteins, which may in
52
53 turn accelerate neurodegenerative processes and cognitive decline. It also implies that the glymphatic
54
55
56
57
58
59
60
61
62
63
64
65

1 pathway may serve as a therapeutic target to preserve cognition in neurodegenerative disease.

2
3 Our results validated a previous study by Park and colleagues and showed that BG-PVS was
4
5 associated with 3-year cognitive decline in patients with PD[11]. In addition, the contribution to poor
6
7 cognitive outcome and the interaction with CSF proteins were specific for PVS located in the basal
8
9 ganglia but not the centrum semiovale. However, the underlying mechanism for the location specificity
10
11 remains unclear. Evidence suggests that cerebral arterial pulsation drove CSF-interstitial fluid exchange
12
13 mediated by the glymphatic pathway [21], and arterial stiffness was associated with a higher BG-PVS
14
15 burden [22]. It is possible that PVS in the basal ganglia may be more prone to arterial damage and
16
17 pulsation change during aging. However, we did not test arterial function, such as arterial stiffness and
18
19 regulation. Future studies will be needed to test this hypothesis. In addition, BG-PVS differs from CS-
20
21 PVS in structure, as BG-PVS is covered by two leptomeningeal membranes and directly connects CSF
22
23 [23]. This means that BG-PVS may be more active in eliminating waste from CSF, and the increased
24
25 visibility of BG-PVS may represent an increased effort in waste clearance. Future studies directly
26
27 comparing CSF dynamics are needed to investigate the location difference of PVS.
28
29
30
31
32
33
34
35
36
37
38

39 Moreover, the results also suggested that PVS visible on MRI may reflect glymphatic dysfunction
40
41 and impaired efflux of CSF proteins in patients with PD. In addition, the level of neurodegenerative
42
43 CSF proteins ($A\beta_{42}$ /tTau) partially mediated the effect of BG-PVS on poor cognitive outcome. Taking
44
45 that CSF proteins, including $A\beta$ and Tau, are toxic to neurons and glial cells [10] and AD biomarkers
46
47 are predictive of cognitive decline in PD [4-6], the result implies that BG-PVS may contribute to
48
49 cognitive decline by elevating toxic CSF proteins in patients with PD. The glymphatic pathway has
50
51 drawn much attention in recent years as a novel pathway to exclude neurotoxic proteins and a potential
52
53 therapeutic target [24]. In patients with superficial sclerosis, PVS was enlarged beneath the affected
54
55
56
57
58
59
60
61
62
63
64
65

1 area where A β was deposited in the cortical arterial wall by biopsy, supporting the notion that enlarged
2
3 PVS is a sign of a blocked drainage pathway by proteins such as A β [25]. Therefore, PVS visible on
4
5
6 MRI may be a possible way to explore the static glymphatic pathway offline.
7

8
9 The interactive effect between BG-PVS and CSF A β_{42} , A β_{42} /tTau, and A β_{42} /pTau on cognitive
10
11 decline was a novel finding in our study. This suggests that modification of the glymphatic pathway
12
13 may be a potential and crucial therapeutic target to alleviate the pathologic effect of A β_{42} and Tau on
14
15 cognitive decline in PD. Emerging evidence has demonstrated the interaction between PVS and AD-
16
17 related proteins [24], and our result further supported the additive consequence of their interaction in
18
19 human cohort. In addition, the benefit of treatment targeting the glymphatic pathway may be beyond
20
21 AD-related pathology since PVS has also been highlighted to be involved in the inflammatory process
22
23 in multiple sclerosis [26] Sleep intervention may be an effective way to improve glymphatic function,
24
25 which may need to be tested in clinical trials or observational studies [27]. Other treatments targeting
26
27 pericytes, endothelial cells, perivascular inflammation and other factors pertaining to glymphatic
28
29 function also deserve to be investigated.
30
31
32
33
34
35
36
37
38

39 In addition to our initial hypothesis, the factors associated with 3-year cognitive decline were
40
41 largely consistent with previous 2-year follow-up analysis [19]. More recently, Irwin and colleagues
42
43 reported that AD-related CSF biomarkers were associated with 3-year cognitive decline in a PPMI
44
45 cohort [20]. Although finding risk factors associated with cognitive decline was not the main topic of
46
47 our study, the consistency with previous data suggests that the present data are representative of the
48
49 whole cohort despite missing BG-PVS data in 59 patients (missing rate = 13.9%).
50
51
52
53
54
55

56 We acknowledge several limitations. First, this study did not measure the dynamic function of the
57
58 glymphatic pathway in vivo. Currently, dynamic fluid exchange by the glymphatic pathway has been
59
60
61
62
63
64
65

1 investigated in vivo by intrathecal injection of the contrast agent in neurological diseases such as
2
3 idiopathic normal pressure hydrocephalus [9, 28]. These approaches enable tracking uptake and
4
5 distribution of tracers dynamically, but they are invasive and may not be applicable in patients with PD.
6
7
8
9 Second, although CSF A β ₄₂ and Tau are consistently found to be associated with cognitive decline in
10
11 PD, they are not PD-specific biomarkers. In addition, the findings of the present study only represent
12
13 the PD population. Whether proteinaceous waste such as A β and Tau drives the increased visibility of
14
15 PVS on MRI and potentially mediates its toxicity needs to be tested in the AD population and normal
16
17 aging population.
18
19
20

21
22 In conclusion, we found that BG-PVS may be independently associated with cognitive decline in
23
24 PD, which may be partially mediated by toxic CSF proteins. The increased visibility of BG-PVS on
25
26 MRI may reflect more advanced glymphatic dysfunction. PVS may serve as a therapeutic target to
27
28 preserve cognition in PD.
29
30
31

32 33 34 35 36 **Conflict of interest**

37
38
39 None
40
41
42
43

44 **Acknowledgements**

45
46
47 PPMI is supported by the Michael J. Fox Foundation for Parkinson's Research and funding partners,
48
49 including Abbott, Avid, Biogen idec, Bristol-Myers Squibb, Covance, Elan, GE Healthcare, Genentech,
50
51 GSK, Lilly, MERCK, MSD, Pfizer, Roche and UCB (details of the PPMI funding partners found at
52
53 www.ppmiinfo.org/ funding partners). Yilong Wang is supported by grants from the National
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1 People's Republic of China (2017YFC1307900), Beijing Outstanding Young Scientist Program
2
3 (BJJWZYJH01201910025030), the third batch of National Ten Thousand Talents Plan, the Beijing
4
5
6 Municipal Science and Technology Commission (Beijing Excellent Talents Training and Supporting
7
8
9 Top Youth Team, D171100003017001 and 2016000021223TD03), and the Youth Beijing Scholar
10
11
12 Program.

13
14
15
16
17 References:

- 18
19
20 [1] G. Alves, K. Bronnick, D. Aarsland, K. Blennow, H. Zetterberg, C. Ballard, M.W. Kurz, U.
21
22 Andreasson, O.B. Tysnes, J.P. Larsen, E. Mulugeta, CSF amyloid-beta and tau proteins, and cognitive
23
24 performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study, J Neurol
25
26 Neurosurg Psychiatry 81(10) (2010) 1080-6.
27
28
29 [2] J.B. Leverenz, G.S. Watson, J. Shofer, C.P. Zabetian, J. Zhang, T.J. Montine, Cerebrospinal fluid
30
31 biomarkers and cognitive performance in non-demented patients with Parkinson's disease, Parkinsonism
32
33 Relat Disord 17(1) (2011) 61-4.
34
35
36 [3] A.L. Stav, D. Aarsland, K.K. Johansen, E. Hessen, E. Auning, T. Fladby, Amyloid-beta and alpha-
37
38 synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease, Parkinsonism Relat
39
40 Disord 21(7) (2015) 758-64.
41
42
43 [4] S. Hall, Y. Surova, A. Ohrfelt, F.S. Swedish Bio, K. Blennow, H. Zetterberg, O. Hansson,
44
45 Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease, Mov Disord 31(6)
46
47 (2016) 898-905.
48
49
50 [5] M. Shahid, J. Kim, K. Leaver, T. Hendershott, D. Zhu, B. Cholerton, V.W. Henderson, L. Tian, K.L.
51
52 Poston, An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients
53
54
55
56
57
58
59
60
61
62
63
64
65

1 with low CSF Ass42 and an APOE epsilon4 allele, *Neurobiol Dis* 127 (2019) 278-286.

2
3 [6] M. Delgado-Alvarado, R. Dacosta-Aguayo, I. Navalpotro-Gomez, B. Gago, A. Gorostidi, H.
4
5 Jimenez-Urbieto, A. Quiroga-Varela, J. Ruiz-Martinez, A. Bergareche, M.C. Rodriguez-Oroz, Ratios of
6
7 proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study, *Mov Disord*
8
9 33(11) (2018) 1809-1813.

10
11 [7] E.L. Boespflug, M.J. Simon, E. Leonard, M. Grafe, R. Woltjer, L.C. Silbert, J.A. Kaye, J.J. Iliff,
12
13 Targeted Assessment of Enlargement of the Perivascular Space in Alzheimer's Disease and Vascular
14
15 Dementia Subtypes Implicates Astroglial Involvement Specific to Alzheimer's Disease, *J Alzheimers Dis*
16
17 66(4) (2018) 1587-1597.

18
19 [8] M.K. Rasmussen, H. Mestre, M. Nedergaard, The glymphatic pathway in neurological disorders,
20
21 *Lancet Neurol* 17(11) (2018) 1016-1024.

22
23 [9] M.J. de Leon, Y. Li, N. Okamura, W.H. Tsui, L.A. Saint-Louis, L. Glodzik, R.S. Osorio, J. Fortea, T.
24
25 Butler, E. Pirraglia, S. Fossati, H.J. Kim, R.O. Carare, M. Nedergaard, H. Benveniste, H. Rusinek,
26
27 Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET, *J Nucl Med* 58(9)
28
29 (2017) 1471-1476.

30
31 [10] S. Jankeviciute, G. Psemeneckiene, R. Morkuniene, E. Grusauskiene, K. Petrikonis, D. Rastenyte,
32
33 V. Borutaite, Cerebrospinal fluids from Alzheimer's disease patients exhibit neurotoxic effects on
34
35 neuronal cell cultures, *Eur J Neurosci* 50(2) (2019) 1994-2006.

36
37 [11] Y.W. Park, N.Y. Shin, S.J. Chung, J. Kim, S.M. Lim, P.H. Lee, S.K. Lee, K.J. Ahn, Magnetic
38
39 Resonance Imaging-Visible Perivascular Spaces in Basal Ganglia Predict Cognitive Decline in
40
41 Parkinson's Disease, *Mov Disord* 34(11) (2019) 1672-1679.

42
43 [12] I. Parkinson Progression Marker, The Parkinson Progression Marker Initiative (PPMI), *Prog*
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Neurobiol 95(4) (2011) 629-35.

2
3 [13] J.M. Wardlaw, E.E. Smith, G.J. Biessels, C. Cordonnier, F. Fazekas, R. Frayne, R.I. Lindley, J.T.
4
5
6 O'Brien, F. Barkhof, O.R. Benavente, S.E. Black, C. Brayne, M. Breteler, H. Chabriat, C. Decarli, F.E.
7
8
9 de Leeuw, F. Doubal, M. Duering, N.C. Fox, S. Greenberg, V. Hachinski, I. Kilimann, V. Mok, R.
10
11
12 Oostenbrugge, L. Pantoni, O. Speck, B.C. Stephan, S. Teipel, A. Viswanathan, D. Werring, C. Chen, C.
13
14
15 Smith, M. van Buchem, B. Norrving, P.B. Gorelick, M. Dichgans, S.T.f.R.V.c.o. nEuroimaging,
16
17
18 Neuroimaging standards for research into small vessel disease and its contribution to ageing and
19
20
21 neurodegeneration, *Lancet Neurol* 12(8) (2013) 822-38.

22
23 [14] F. Fazekas, R. Kleinert, H. Offenbacher, R. Schmidt, G. Kleinert, F. Payer, H. Radner, H. Lechner,
24
25
26 Pathologic correlates of incidental MRI white matter signal hyperintensities, *Neurology* 43(9) (1993)
27
28
29 1683-9.

30
31 [15] F.N. Doubal, A.M. MacLulich, K.J. Ferguson, M.S. Dennis, J.M. Wardlaw, Enlarged perivascular
32
33
34 spaces on MRI are a feature of cerebral small vessel disease, *Stroke* 41(3) (2010) 450-4.

35
36 [16] G.M. Potter, F.N. Doubal, C.A. Jackson, F.M. Chappell, C.L. Sudlow, M.S. Dennis, J.M. Wardlaw,
37
38
39 Enlarged perivascular spaces and cerebral small vessel disease, *Int J Stroke* 10(3) (2015) 376-81.

40
41
42 [17] J.H. Kang, B. Mollenhauer, C.S. Coffey, J.B. Toledo, D. Weintraub, D.R. Galasko, D.J. Irwin, V.
43
44
45 Van Deerlin, A.S. Chen-Plotkin, C. Caspell-Garcia, T. Waligorska, P. Taylor, N. Shah, S. Pan, P. Zero,
46
47
48 M. Frasier, K. Marek, K. Kieburz, D. Jennings, C.M. Tanner, T. Simuni, A. Singleton, A.W. Toga, S.
49
50
51 Chowdhury, J.Q. Trojanowski, L.M. Shaw, I. Parkinson's Progression Marker, CSF biomarkers
52
53
54 associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers
55
56
57 Initiative study, *Acta Neuropathol* 131(6) (2016) 935-49.

58
59 [18] B. Mollenhauer, C.J. Caspell-Garcia, C.S. Coffey, P. Taylor, L.M. Shaw, J.Q. Trojanowski, A.
60
61
62

1 Singleton, M. Frasier, K. Marek, D. Galasko, I. Parkinson's Progression Marker, Longitudinal CSF
2
3 biomarkers in patients with early Parkinson disease and healthy controls, *Neurology* 89(19) (2017) 1959-
4
5
6 1969.

7
8
9 [19] A. Schrag, U.F. Siddiqui, Z. Anastasiou, D. Weintraub, J.M. Schott, Clinical variables and
10
11 biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease:
12
13 a cohort study, *Lancet Neurol* 16(1) (2017) 66-75.

14
15
16 [20] D.J. Irwin, J. Fedler, C.S. Coffey, C. Caspell-Garcia, J.H. Kang, T. Simuni, T. Foroud, A.W. Toga,
17
18
19 C.M. Tanner, K. Kieburtz, L.M. Chahine, A. Reimer, S. Hutten, D. Weintraub, B. Mollenhauer, D.R.
20
21 Galasko, A. Siderowf, K. Marek, J.Q. Trojanowski, L.M. Shaw, I. Parkinson's Progression Marker,
22
23 Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease, *Ann*
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

[21] J.J. Iliff, M. Wang, D.M. Zeppenfeld, A. Venkataraman, B.A. Plog, Y. Liao, R. Deane, M.
Nedergaard, Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine
brain, *J Neurosci* 33(46) (2013) 18190-9.

[22] I. Riba-Llena, J. Jimenez-Balado, X. Castane, A. Girona, A. Lopez-Rueda, X. Mundet, C.I. Jarca, J.
Alvarez-Sabin, J. Montaner, P. Delgado, Arterial Stiffness Is Associated With Basal Ganglia Enlarged
Perivascular Spaces and Cerebral Small Vessel Disease Load, *Stroke* 49(5) (2018) 1279-1281.

[23] J.M. Wardlaw, H. Benveniste, M. Nedergaard, B.V. Zlokovic, H. Mestre, H. Lee, F.N. Doubal, R.
Brown, J. Ramirez, B.J. MacIntosh, A. Tannenbaum, L. Ballerini, R.L. Rungta, D. Boido, M. Sweeney,
A. Montagne, S. Charpak, A. Joutel, K.J. Smith, S.E. Black, D. colleagues from the Fondation Leducq
Transatlantic Network of Excellence on the Role of the Perivascular Space in Cerebral Small Vessel,
Perivascular spaces in the brain: anatomy, physiology and pathology, *Nat Rev Neurol* 16(3) (2020) 137-

1 153.

2
3 [24] B.L. Sun, L.H. Wang, T. Yang, J.Y. Sun, L.L. Mao, M.F. Yang, H. Yuan, R.A. Colvin, X.Y. Yang,
4
5
6 Lymphatic drainage system of the brain: A novel target for intervention of neurological diseases, *Prog*
7
8
9 *Neurobiol* 163-164 (2018) 118-143.

10
11 [25] A. Keable, K. Fenna, H.M. Yuen, D.A. Johnston, N.R. Smyth, C. Smith, R. Al-Shahi Salman, N.
12
13 Samarasekera, J.A. Nicoll, J. Attems, R.N. Kalara, R.O. Weller, R.O. Carare, Deposition of amyloid
14
15 beta in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in
16
17 cerebral amyloid angiopathy, *Biochim Biophys Acta* 1862(5) (2016) 1037-46.

18
19 [26] J. Wuerfel, M. Haertle, H. Waiczies, E. Tysiak, I. Bechmann, K.D. Wernecke, F. Zipp, F. Paul,
20
21
22 Perivascular spaces--MRI marker of inflammatory activity in the brain?, *Brain* 131(Pt 9) (2008) 2332-
23
24
25
26
27
28 40.

29
30 [27] E. Cvejic, S. Huang, U. Vollmer-Conna, Can you snooze your way to an 'A'? Exploring the complex
31
32 relationship between sleep, autonomic activity, wellbeing and performance in medical students, *Aust N*
33
34
35
36
37
38 *Z J Psychiatry* 52(1) (2018) 39-46.

39 [28] G. Ringstad, S.A.S. Vatnehol, P.K. Eide, Glymphatic MRI in idiopathic normal pressure
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65 hydrocephalus, *Brain* 140(10) (2017) 2691-2705.

1 **Figure legends**

2
3 **Figure 1. Correlation between CSF biomarkers and cognitive outcomes stratified by BG-PVS**

4
5
6 BG-PVS modified the effect of $A\beta_{42}/t\text{Tau}$ (A), $A\beta_{42}/p\text{Tau}$ (B), $A\beta_{42}$ (C) on cognitive outcome in
7
8
9 Parkinson's disease, as high BG-PVS group showed steeper decline in the MoCA score in relation to
10
11
12 CSF biomarkers at the 3-year follow-up.

13
14 Abbreviations: BG-PVS, basal-ganglia perivascular space; CSF, cerebrospinal fluid.

15
16
17 **Figure 2. Path analysis**

18
19
20 A. CSF $A\beta_{42}/t\text{Tau}$, but not $A\beta_{42}/p\text{Tau}$ or CSF $A\beta_{42}$ significantly mediated the effect of BG-PVS on
21
22
23 cognitive decline in patients with PD. The effect of WMH (B) or CS-PVS (C) on cognitive outcome
24
25
26 was not mediated by CSF biomarkers.

27
28 Abbreviations: BG-PVS, basal-ganglia perivascular space; CSF, cerebrospinal fluid; WMH, white
29
30
31 matter hyperintensity.

32
33
34
35
36 Supplementary figures:

37
38
39 **FIG. S1. Correlation between CSF biomarkers**

40
41
42 Abbreviations: CSF, cerebrospinal fluid.

43
44
45 **FIG. S2. Correlation between CSF biomarkers and cognitive decline stratified by the presence of**
46
47 **cardiovascular disease**

48
49
50 The presence of cardiovascular disease did not modify the effect of CSF biomarkers on cognitive
51
52
53 decline in patients with PD.

54
55
56 **FIG. S3. Path analysis for WMH, CS-PVS and CSF biomarkers**

57
58
59 CSF biomarkers did not mediate the effect of WMH or CS-PVS on cognitive decline in PD.

Table 1. Demographic information between groups stratified by BG-PVS

	PD with low BG- PVS (N = 286)	PD with high BG- PVS (N = 55)	P value
<i>Demographic</i>			
Age (median, IQR, year)	60.7 (53.5–66.6)	71.1 (67.1–74.8)	<0.001
Gender (F/M)	100/188	15/40	0.269
<i>Disease profile</i>			
Disease duration (median, IQR, month)	4 (2–7)	6 (3–13)	0.066
MoCA Score (median, IQR)	28 (26–29)	27 (25–29)	0.222
Hoehn-Yahr staging (median, IQR)	2 (1–2)	2 (2–2)	0.001
MDS-UPDRS III total (median, IQR)	19 (14–26)	22 (16–27)	0.024
State Trait Anxiety Score (median, IQR)	94 (89–98)	94 (88–97)	0.500
Geriatric Depression Scale (median, IQR)	5 (5–6)	5 (4–6)	0.280
<i>CSF biomarkers</i>			
CSF α -synuclein (median, IQR, pg/ml)	1351.3 (1029.3– 1718.0)	1528.8 (1164.3– 2086.0)	0.016
CSF A β ₄₂ (median, IQR, pg/mL)	848.6 (615.1– 1119.0)	822.2 (627.9– 1050.5)	0.860
CSF pTau (median, IQR, pg/mL)	13.0 (10.9–16.7)	15.4 (12.4–21.4)	0.001
CSF tTau (median, IQR, pg/mL)	152.6 (124.0– 192.6)	186.4 (147.2– 237.7)	<0.001
CSF A β ₄₂ /tTau	5.81 (4.69–6.69)	4.88 (3.71–6.01)	0.002

CSF A β ₄₂ /pTau	69.4 (57.4–80.3)	61.1 (42.7–75.7)	0.002
<i>DAT striatal binding ratios</i>			
Mean caudate uptake (median, IQR)	2.02 (1.67–2.37)	1.88 (1.54–2.21)	0.155
Mean putamen uptake (median, IQR)	1.79 (1.48–2.18)	1.77 (1.34–2.08)	0.270
Caudate asymmetry (median, IQR)	1.19 (1.10–1.31)	1.17 (1.07–1.27)	0.216
Putamen asymmetry (median, IQR)	1.45 (1.19–1.76)	1.39 (1.17–1.73)	0.484
<i>Small vessel disease profile</i>			
WMH Fazekas score (median, IQR)	2 (1–2)	3 (2–4)	<0.001
Cardiovascular diseases (N, %)	224 (52.1%)	57 (77.0%)	<0.001
Cerebrovascular diseases (N, %) ^a	2 (0.5%)	2 (2.7%)	0.195
<i>Genetic profile</i>			
Presence of APOE ϵ 4 allele (N, %)	68 (23.8%)	13 (23.6)	0.982
<i>Cognition at 3-year follow-up</i>			
Change in MoCA score (median, IQR)	0 (-2–1)	-2 (-5–0.25)	0.004
Cognitive impairment (N, %)	46 (18.9)	22 (48.9%)	<0.001

^aCorrection for continuity was adapted for inadequate event.

Abbreviations: CSF, cerebrospinal fluid; DAT, dopaminergic transporter; IQR, interquartile range;

MDS-UPDRS III, Movement Disorder Society Unified Parkinson's Disease Rating Score part III;

MoCA, Montreal Cognitive Assessment.

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 2. Linear mixed model for interactive effect of CSF markers and BG-PVS on cognitive outcomes

	MoCA score at 3-year follow-up				Change in MoCA from baseline to 3-year follow-up			
	Model without interaction		Model with interaction		Model without interaction		Model with interaction	
	Coefficient	P value	Coefficient	P value	Coefficient	P value	Coefficient	P value
Model 1								
Baseline A β ₄₂ /tTau	0.385 (0.153–0.617)	0.001	1.060 (0.619–1.500)	<0.001	0.382 (0.149–0.614)	0.001	1.055 (0.615–1.496)	<0.001
BG-PVS \geq 2	REF		REF				REF	
BG-PVS<2	1.283 (0.287–2.279)	0.012	6.000 (3.174–8.826)	<0.001	1.322 (0.326–2.318)	0.010	6.012 (3.187–8.836)	<0.001
A β ₄₂ /tTau*BG-PVS	/		-0.911 (-1.420–-0.400)	0.001	/		-0.907 (-1.416–-0.397)	0.001
Interaction								
AIC	815.5		804.5		817.3		806.3	
Model 2								
Baseline A β ₄₂ /pTau	0.031 (0.011–0.050)	0.002	0.092 (0.056–0.129)	<0.001	0.030 (0.011–0.050)	0.003	0.093 (0.056–0.129)	<0.001

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

BG-PVS \geq 2	REF		REF			REF		
BG-PVS<2	1.309 (0.267–2.350)	0.014	6.580 (3.740–9.419)	<0.001	1.359 (0.317–2.400)	0.011	6.602 (3.763–9.441)	<0.001
A β ₄₂ /pTau*BG-PVS interaction			-0.08 (-0.13–0.04)	<0.001			-0.084 (-0.126–0.042)	<0.001
AIC	774.7		765.8		776.4		767.5	
<hr/>								
Model 3								
Baseline A β ₄₂	0.001 (0.000–0.002)	0.035	0.003 (0.001–0.005)	0.004	0.001 (0–0.002)	0.038	0.003 (0.001–0.005)	0.004
BG-PVS \geq 2	REF		REF				REF	
BG-PVS<2	1.258 (0.252–2.263)	0.015	3.184 (1.084–5.285)	0.003	1.326(0.321–2.330)	0.010	3.301 (1.207–5.396)	0.002
A β ₄₂ *BG-PVS interaction			-0.002 (-0.004–0.000)	0.039			-0.002 (-0.004–0)	0.035
AIC	859.9		867.5		861.5		868.9	

CSF biomarkers (A β ₄₂, A β ₄₂/tTau, A β ₄₂/pTau), BG-PVS and their interaction were fixed effect. Age, baseline MoCA score, RBDSQ, and DAT putamen asymmetry were set as random effect for MoCA score at 3-year follow-up, and baseline state trait anxiety inventory was additionally set as random effect for 3-year change in MoCA; Abbreviations:

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

AIC, Akaike information criterion; BG-PVS, basal ganglia perivascular space; REF, reference.

Perivascular Space in Parkinson's ~~disease~~Disease: Association with CSF Amyloid/Tau and Cognitive ~~D~~decline

Huimin Chen^{a,b,c,d}, Huijuan Wan^{b,c,d,e}, Meimei Zhang^{b,c,d}, Joanna M Wardlaw^f, Tao Feng^{b,c,d}, Yilong Wang^{b,c,d}

^aDepartment of Neurology, Beijing Hospital, National Center of Gerontology- Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China

^bDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

^cChina National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing, China

^dAdvanced Innovation Center for Human Brain Projection, Capital Medical University, Beijing, China

^eDepartment of Neurology, First Affiliated Hospital, Xiamen University, Xiamen, China

^fCentre for Clinical Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK

Corresponding author:

Yilong Wang*, MD, PhD.

Address: China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing, China. 100070.

E-mail: yilong528@gmail.com, Tel: +86-139-1166-6571;

Keywords/Search terms: Parkinson's disease; Perivascular Space; Cognition; Amyloid; Tau

Title: 97 characteristics; Tables: 2; Figures:2; supplementary table: 4; supplementary figure 3;

[supplementary result:1](#); Reference:[2829](#);

Word count: abstract 249; body of the manuscript ~~326233~~4208;

Abstract

Objective: Whether perivascular space (PVS) visible on magnetic resonance imaging (MRI) represents glymphatic dysfunction and whether this imaging marker is pathologic in Parkinson's disease (PD) have been controversial. The objective was to determine whether PVS visible on MRI is independently associated with cognitive decline in patients with PD, and to test whether pathologic proteins in the CSF (such as $A\beta_{42}$) mediate the pathologic role of PVS.

Methods: A total of 341 patients with Parkinson's disease from Parkinson's Progression Marker Initiative (PPMI) cohort was included in the present study. PVS in the basal ganglia (BG-PVS) and centrum semiovale were evaluated with a semiquantitative scale. Changes in the Montreal Cognitive Assessment (MoCA) score and the absolute MoCA score at the 3-year assessment were considered the main cognitive outcome. A multivariable linear regression model was used to test the association between PVS and cognitive decline. A mixed linear model and path analysis were used to test the interaction among PVS, CSF biomarkers and cognitive decline.

Results: BG-PVS was associated with cognitive decline in patients with PD at the 3-year follow-up independent of age, baseline cognition, motor and nonmotor function, presynaptic dopaminergic deficiency, and CSF biomarkers. The interaction between BG-PVS and $A\beta_{42}/t\text{Tau}$, $A\beta_{42}/p\text{Tau}$, and $A\beta_{42}$ levels was significantly predictive of 3-year cognitive decline. Path analysis confirmed that CSF $A\beta_{42}/t\text{Tau}$ levels partially mediated the pathologic effect of BG-PVS on cognitive outcome in PD.

Conclusions: BG-PVS is independently associated with cognitive decline in PD, and this association may be partially mediated by toxic CSF proteins.

Keywords: Parkinson's disease; Perivascular Space; Cognition; Amyloid; Tau

1. Introduction

Parkinson's disease (PD) is the second most common neurodegenerative disease, with α -synuclein (α -syn) aggregation and Lewy body deposition being the pathologic hallmarks. Previous studies from several cohorts consistently reported that Alzheimer's disease (AD)-related CSF biomarkers (i.e., lower levels of $A\beta_{42}$ and $A\beta_{42}$ /Tau ratios and higher levels of total and phosphorylated Tau) were associated with cognitive impairment in PD ~~cross-sectionally [1-3] and longitudinally [1-3]~~ [1-3].

Emerging evidence has highlighted the role of the perivascular space (PVS) as a glymphatic pathway for waste clearance in the brain and demonstrated that glymphatic dysfunction reduced cerebrospinal fluid (CSF) clearance of $A\beta$ in AD models and in patients with AD [4-6]. Since AD-related proteins are toxic to neurons and glial cells [7] and are associated with cognitive decline in AD and PD [1-3], it is possible that reduced CSF clearance of toxic proteins as a result of glymphatic dysfunction may aggregate the neurodegenerative process and facilitate the development of dementia.

~~Indeed, patients with PD showed impaired meningeal lymphatic drainage assessed by dynamic contrast-enhanced magnetic resonance imaging (MRI), which may facilitate the α -syn deposition and result in motor dysfunction in PD mice model [8]. A previous cohort from Korea demonstrated that basal ganglia PVS (BG-PVS) visible on MRI predicted cognitive decline in PD at the 5-year follow-up [9][10]. This result needs to be validated in other cohorts. In addition, if BG-PVS visible on MRI reflects glymphatic dysfunction, there might be an association between the severity of BG-PVS visible on MRI and higher neurodegenerative burden measured by CSF biomarkers such as $A\beta$.~~

The Parkinson's Progression Marker Initiative (PPMI) is the largest ongoing cohort of PD with comprehensive clinical, imaging and CSF biomarker data. The PPMI provides an opportunity to confirm the pathologic role of BG-PVS in PD cognitive outcome. In addition, it provides superb data to

test the relationship between PVS visible on MRI and neurodegenerative burden measured by CSF biomarkers, which may inform the mechanism and potential therapeutic target of PVS in progressive neurodegenerative processes. [In the current analysis of PPMI data, we hypothesized that BG-PVS may be related with cognitive decline in PD, which may be mediated by CSF neurodegenerative biomarkers.](#)

2. Method

2.1 Study design and participants

PPMI is an ongoing, multicenter, longitudinal, observational study that started in 2010 (<https://www.ppmi-info.org/>). Patients with early, drug-naïve PD and intact cognition were included. The PPMI study was approved by the institutional review board at each site, and participants provided written informed consent to participate. The protocol and more detailed study design of PPMI has been described elsewhere [9]. From the whole PPMI cohort, only PD patients with complete baseline BG-PVS profiles and CSF biomarkers were included in the present analysis. The data used in the current study were downloaded from the PPMI dataset in June 2020.

2.2 Outcome measurements

Cognitive decline was evaluated using the change in the MoCA score from baseline to 3-year follow-up and the absolute MoCA score at the 3-year assessment. ~~The Hopkins Verbal Learning Test (HVLT) (memory), the Benton Judgment of Line Orientation-15-item version (visuospatial function), the Symbol Digit Modalities Test (processing speed), the Letter Number Sequencing (executive function and working memory), and the semantic (animal) fluency test (language) were also performed.~~ Motor function was measured using the Movement Disorder Society Unified Parkinson's Disease Rating

Scale (MDS-UPDRS) part III and Hoehn-Yahr stage. The MDS-UPDRS III score was further divided into four subscores according to the cardinal motor symptoms in PD: tremor (items 15-18), bradykinesia (items 4-8, and item 14), rigidity (item 3), and axial signs (items 1, 2, 9-13). Nonmotor symptoms in the prediction of cognitive decline in PD included rapid eye movement behavior disorder (RBD), which was assessed with the RBD Screening Questionnaire (RBDSQ); sense of smell, which was assessed with the University of Pennsylvania Smell Identification Test (UPSIT); depression, which was assessed with the 15-item Geriatric Depression Scale (GDS); and anxiety, which was assessed with the State-Trait Anxiety Inventory.

2.3 DAT imaging

[123I]β-CIT DAT single-photon emission computed tomography (SPECT) imaging was acquired at PPMI imaging centers in accordance with the PPMI imaging protocol. Mean caudate and putaminal uptake relative to uptake in the occipital area and asymmetry of caudate and putaminal uptake (side with highest divided by side with lowest uptake) were computed for the analysis.

2.4 History of cardio- and cerebrovascular diseases and risk factors

Histories of cardio- and cerebrovascular diseases were recorded in the PPMI cohort at patient screening. Cardiovascular diseases ~~and risk factors~~ include a history of diabetes, hypertension, hyperlipidemia, hypercholesterolemia, and cardiac diseases. Cerebrovascular diseases included a history of cerebrovascular accident, transient ischemic attack, ischemic stroke, cervical and carotid stenosis or occlusion.

2.5 Imaging markers of cerebral small vessel disease

Imaging markers of cerebral small vessel disease (CSVD) were evaluated by a neurologist who was

blind to the patient information (HJ Wan) following the instruction and definition of Standards for Reporting Vascular changes on neuroimaging (STRIVE) [10]. White matter hyperintensity (WMH) was rated according to the Fazekas rating scale [11]. Perivascular space was defined on MRI as small, sharply delineated structures of CSF intensity (or close to CSF intensity) following the course of perforating vessels. PVS in the basal ganglia and centrum semiovale (CS-PVS) were rated separately on T2 weighted sequence as 0 = none, 1 = 1–10, 2 = 11–20, 3 = 21–40, and 4 = >40 PVS per side, and the worse side was used if there was asymmetry [12, 13]. In the statistical analysis for BG-PVS, patients were stratified into groups with moderate-to-severe BG-PVS (BG-PVS rating \geq 2) and none-to-mild BG-PVS (BG-PVS rating $<$ 2). Similarly, in the analysis for WMH and CS-PVS, patients were also grouped into the high WMH group (Fazekas $>$ 2) versus the low WMH group (Fazekas \leq 2) and the high CS-PVS group (CS-PVS rating \geq 2) versus the low CS-PVS group (CS-PVS rating $<$ 2). This stratification was consistent with the distribution of CSVD profiles in our data and was consistent with studies showing that BG-PVS rating \geq 2 (moderate to severe) was predictive of unfavorable outcomes [12, 13].

2.6 Genotyping

At the screening visit, genomic DNA was extracted from whole blood of the subject. The APOE genotype was analyzed at the PPMI genetic core as previously described [14]. Subjects were classified by the presence or absence of *APOE* ϵ 4 genotypes.

2.7 CSF biomarkers

The concentration of α -synuclein in CSF samples was analyzed using an ELISA assay available commercially from BioLegend. CSF A β ₄₂, total tau (tTau) and tau phosphorylated at the threonine 181 position (pTau) were analyzed at Biorepository Core laboratories to the University of Pennsylvania

using Elecsys electrochemiluminescence immunoassays (Roche Diagnostics). More detail and primary results of the measured CSF biomarkers have been reported previously in the PPMI cohort [14, 15].

2.8 Statistics

Continuous variables were compared between groups using the Mann-Whitney test (nonnormal distribution) or two sample t test (normal distribution), and categorical variables were compared between groups using the Chi-square test. Univariable and multivariable linear regression models were performed using the MoCA score at the 3-year follow-up and the 3-year change in the MoCA score as separate dependent variables. The regression models consulted a previous PPMI study using 2-year cognitive outcomes [16]. Multivariable regression models were conducted with adjustment of ~~V~~variables showing a ~~tendency to~~ significant association ($p < 0.05$) in the univariable regression ~~analysis further entered the multivariable linear regression analysis simultaneously, while~~ ~~(only one~~ significant variable of the same feature with lower P value was selected to avoid collinearity) ~~), and~~ variables that showed significantly unbalanced features between BG-PVS groups. As CSF biomarkers were significantly correlated with each other (supplementary figure 1)[17], each biomarker entered the multivariable regression model separately.

The interaction between BG-PVS and CSF biomarkers in relation to cognition was first explored by plotting the fitting curve and then by linear mixed models. The change in MoCA score and MoCA score at the 3-year follow-up was used as dependent variables in linear mixed models. BG-PVS severity and CSF biomarker with or without interaction term were set as fixed effects, and other variables showing significant association with cognitive outcomes in multivariable univariable regression ~~and~~ unbalanced features between BG-PVS groups were used as random effects. The Akaike information criterion (AIC) of models with and without the BG-PVS*CSF biomarker

interaction item was recorded. Path analysis was conducted to investigate how much CSF biomarkers mediated the effect of BG-PVS on cognition in PD. The standardized coefficient (β) of BG-PVS without a mediation effect (direct effect) and with a mediation effect (indirect effect) and the standardized coefficient (β) of the CSF biomarker on the change in MoCA were calculated. P value < 0.05 was defined as significant. Group comparison of CSF biomarkers at each follow-up point was also performed between PD groups with different BG-PVS severities. P value < 0.01 was defined as significant in this group comparison for multiple comparison correction ([Bonferroni](#) correction for 4 repeated comparisons [for each CSF biomarker](#)). Group comparison was conducted in SPSS 25.0 (SPSS, inc., Beijing, China), and linear regression and linear mixed models were performed in R software version 4.02 (<https://www.r-project.org/>).

To rule out confounding by ~~other CSVD markers WMH and lacune~~, and to investigate the location specificity of PVS, their relationships ~~among (WMH, the presence of lacune or CS-PVS)~~ with CSF biomarkers, and cognitive decline ~~were~~ further explored using a similar statistical approach.

2.9 Data Availability Statement

The data was publicly available on PPMI website (<https://www.ppmi-info.org/access-data-specimens/>).

3. Results

3.1 Baseline features of the included patients

Four hundred and twenty-three patients with drug-naïve PD were recruited in PPMI cohort. Among these subjects, MRI imaging or T2-weighted imaging was missing in 47 patients, and imaging in another 13 patients was not qualified to rate BG-PVS due to incomplete or nonaxial slices. CSF biomarkers were missing in another 22 patients with PD. Finally, 341 patients with complete baseline

Formatted: Font: (Default) Times New Roman

PVS and CSF biomarkers were included in the present analysis. The included and excluded patients showed overall similar demographic and behavioral profiles (supplementary table 1).

3.2 Group comparison between patients with lower and higher BG-PVS burdens

Compared with patients with lower BG-PVS burden, patients with more severe BG-PVS were significantly older; had more impaired motor function at baseline; had a higher prevalence of previous cardiovascular disease; ~~had a higher prevalence of and the presence of lacune presence~~, and more severe WMH at baseline; had a higher risk of cognitive impairment and a greater decline in the MoCA score at the 3-year follow-up despite of similar baseline MoCA scores; and showed lower levels of CSF ~~A β ₄₂ α -synuclein~~, A β ₄₂/tTau, A β ₄₂/pTau and higher levels of CSF ~~α -syn~~, tTau and pTau at baseline (Table 1).

3.3 ~~Univariate-Univariable~~ linear regression for cognition at the 3-year follow-up

Using the absolute MoCA score at the 3-year follow-up as the dependent variable, age, baseline MoCA score, MDS-UPDRS III ~~total score~~, ~~tremor, bradykinesia, and axial subscores~~, RBDSQ, UPSIT score, CSF A β ₄₂, tTau, pTau, A β ₄₂/tTau, A β ₄₂/pTau, putamen asymmetry and BG-PVS were significantly associated with cognition at the 3-year follow-up in PD patients (P<0.05).

Using decline in MoCA score as the dependent variable, age, baseline MoCA score, RBDSQ, UPSIT score, ~~axial subscore of MDS-UPDRS III~~, CSF A β ₄₂, tTau, pTau, A β ₄₂/tTau, A β ₄₂/pTau, putamen asymmetry, and BG-PVS were significantly associated with cognitive decline during three years in PD patients (P<0.05) (supplementary table 2).

3.4 Multivariable linear regression for cognition at the 3-year follow-up

In multivariable regression models, BG-PVS was significantly associated with MoCA score or change in MoCA score, independent of ~~age, past-history cardiovascular diseases, baseline MoCA~~.

~~score, axial subscore of MDS-UPDRS III, RBDSQ, UPSIT, putamen asymmetry, WMH Fazekas score, and the presence of lacunes, and CSF biomarkers. Age, baseline cognition, motor function, nonmotor symptoms, presynaptic dopaminergic deficiency, and CSF biomarkers.~~ Baseline CSF A β ₄₂, A β ₄₂/tTau and A β ₄₂/pTau were significantly associated with the MoCA score or change in the MoCA score at 3-year follow-up independent of ~~age, past-history cardiovascular diseases, baseline MoCA score, axial subscore of MDS-UPDRS III, RBDSQ, UPSIT, putamen asymmetry, WMH Fazekas score, the presence of lacune, and -BG-PVCSF biomarkers, age, baseline cognition, motor function, nonmotor symptoms, presynaptic dopaminergic deficiency, and BG-PVS.~~ However, baseline CSF tTau and pTau were not significantly associated with either cognitive outcome at year three after adjustment (supplementary table 3).

3.5 Interaction between CSF biomarkers and BG-PVS

There was a significant main effect of BG-PVS and CSF A β ₄₂/tTau, A β ₄₂/pTau and A β ₄₂ as well as interactions between BG-PVS and these CSF biomarkers (**Table 2**), such that patients with higher BG-PVS and lower A β ₄₂/tTau (**Figure 1A**), A β ₄₂/pTau (**Figure 1B**), or A β ₄₂ (**Figure 1C**) showed steeper decline in the MoCA score at the 3-year follow-up. Models containing interaction terms provided a slightly improved fit. As patients with a higher BG-PVS burden had a higher prevalence of cardiovascular disease ~~and risk factors~~, we further tested whether the interaction between BG-PVS and CSF biomarkers was confounded by the presence of cardiovascular disease ~~and risk factors~~. However, the correlation between CSF biomarkers and cognitive decline was not stratified by the presence of cardiovascular disease ~~or related risk factors~~ (supplementary figure 2).

We further compared CSF biomarkers at each follow-up timepoint between the BG-PVS groups. The results revealed that patients with more severe BG-PVS showed significantly higher levels of all

measured CSF biomarkers at baseline, 1-year follow-up, and 2-year follow-up, and the significant difference in tTau and pTau was still observed at year three ([supplementary table 4](#)) with corrected P values ($P < 0.01$) ([supplementary table 4](#)).

3.6 Path analysis

In path analysis, CSF $A\beta_{42}/tTau$ was found to mediate the effect of BG-PVS on cognitive decline (total effect [original coefficient] = -0.256, direct effect [corrected coefficient] = -0.208, indirect effect = -0.048) (**Figure 2A**). That is, CSF $A\beta_{42}/tTau$ mediated 18.8% (indirect effect/total effect) of the BG-PVS effect on the decrease in MoCA scores during the 3-year follow-up. In path analysis, the correlation of BG-PVS with $A\beta_{42}/pTau$ was marginally significant, and that with $A\beta_{42}$ was not significant (**Figure 2B and 2C**).

3.7 Additional analysis with WMH and CS-PVS

To rule out the confounding effect of WMH, lacune and CS-PVS, additional analysis was performed. No significant association was found among WMH, CSF biomarkers, and cognitive outcome; among the presence of lacune, CSF biomarkers, and cognitive outcome; and among CS-PVS, CSF biomarkers, and cognitive outcome (see supplementary figure 3 and supplementary result). For WMH, no significant difference in baseline CSF biomarkers (α -syn $z = -1.337$, $P = 0.181$; $A\beta_{42}$ $z = -0.430$, $P = 0.667$; pTau $z = -1.181$, $P = 0.238$; tTau $z = -1.697$, $P = 0.090$) was found between groups with different WMH severity (Fazekas 0-2 vs. Fazekas 3-6). No significant correlation was found between CSF biomarkers and WMH Fazekas rating according to the Spearman correlation analysis (α -syn $r = 0.025$, $P = 0.640$; $A\beta_{42}$ $r = -0.057$, $P = 0.300$; pTau $r = 0.036$, $P = 0.534$; tTau $r = 0.039$, $P = 0.331$). No significant correlation was observed between WMH and cognitive decline or between WMH and CSF biomarkers ($A\beta_{42}/tTau$, $A\beta_{42}/pTau$, $A\beta_{42}$) in the path analysis (supplementary figure 3).

~~For CS-PVS, no significant difference in baseline CSF biomarkers (α -syn $z = -1.391$, $P = 0.164$; $A\beta_{42}$ $z = -0.685$, $P = 0.493$; pTau $z = -1.422$, $P = 0.155$; tTau $z = -1.741$, $P = 0.082$) was found between groups stratified by CS-PVS severity (CS-PVS 0-1 vs. CS-PVS ≥ 2). No significant correlation was observed between CS-PVS and CSF biomarkers ($A\beta_{42}/tTau$, $A\beta_{42}/pTau$, $A\beta_{42}$) in path analysis (supplementary figure 3). Although a marginally significant correlation between CS-PVS and cognitive decline was observed in the path analysis, the significant correlation was not preserved in the multivariable linear model adjusting for age (coefficient = -0.729 , 95% CI = -1.612 -0.154 , $P = 0.105$) or in the model adjusted for age, baseline MoCA scores, baseline state trait anxiety score, RBDSQ, UPSIT, and putamen asymmetry (coefficient = -0.615 , 95% CI = -1.419 -0.188 , $P = 0.132$).~~

Formatted: Indent: First line: 0 ch

4. Discussion

This is the first study that examined the relationship ~~between among~~ CSF biomarkers, ~~cognitive outcome~~ and PVS visible on MRI in ~~neurodegenerative disease~~PD. The main finding demonstrated that BG-PVS was independently associated with cognitive decline in patients with PD. In addition, BG-PVS modified the pathologic effect of $A\beta_{42}/tTau$, $A\beta_{42}/pTau$, and $A\beta_{42}$ on cognitive decline in PD. Path analysis confirmed that CSF biomarkers, especially $A\beta_{42}/tTau$, partially mediated the pathologic effect of BG-PVS on cognitive outcomes in PD. These results suggest that the increased visibility of BG-PVS on MRI may reflect more advanced glymphatic dysfunction, resulting in higher levels of toxic CSF proteins, which may in turn accelerate neurodegenerative processes and cognitive decline. It also implies that the glymphatic pathway may serve as a therapeutic target to preserve cognition in neurodegenerative disease.

Our results validated a previous study by Park and colleagues ~~and showed that BG-PVS was~~

~~associated with 3-year cognitive decline in patients with PD [18], and showed that BG-PVS was associated with 3-year cognitive decline in patients with PD.~~ In addition, the contribution to poor cognitive outcome and the interaction with CSF proteins were specific for PVS located in the basal ganglia but not the centrum semiovale. However, the underlying mechanism for the location specificity remains unclear. Evidence suggests that cerebral arterial pulsation drove CSF-interstitial fluid exchange mediated by the glymphatic pathway [19], and arterial stiffness was associated with a higher BG-PVS burden [20]. It is possible that PVS in the basal ganglia may be more prone to arterial damage and pulsation change during aging. However, we did not test arterial function, such as arterial stiffness and regulation. Future studies will be needed to test this hypothesis. In addition, BG-PVS differs from CS-PVS in structure, as BG-PVS is covered by two leptomeningeal membranes and directly connects CSF [21]. This means that BG-PVS may be more active in eliminating waste from CSF, and the increased visibility of BG-PVS may represent an increased effort in waste clearance. Future studies directly comparing CSF dynamics are needed to investigate the location difference of PVS.

Moreover, the results ~~also~~ suggested that PVS visible on MRI may reflect glymphatic dysfunction, ~~and impaired~~ efflux of CSF proteins ~~and more advanced neurodegeneration~~ in patients with PD. ~~Previous evidence suggested that patients with PD showed higher volume fraction of PVS, especially for those familial patients with genetic mutation [22]. Previous PPMI result data also suggested that PVS in midbrain was associated with neurodegenerative imaging marker— (DAT deficiency) [23]. These findings supported our hypothesis that PVS visible on MRI may be closely linked with neurodegeneration in patients with PD. We found that~~ ~~In addition,~~ the level of neurodegenerative CSF proteins ($A\beta_{42}$ /tTau) partially mediated the effect of BG-PVS on poor cognitive outcome. Taking that CSF proteins, including $A\beta$ and Tau, are toxic to neurons and glial cells [7] and AD biomarkers are

predictive of cognitive decline in PD [1-3], the result implies that BG-PVS may contribute to cognitive decline by elevating toxic CSF proteins in patients with PD.

The glymphatic pathway has drawn much attention in recent years as a novel pathway to exclude neurotoxic proteins and a potential therapeutic target [24]. In patients with superficial sclerosis, PVS was enlarged beneath the affected area where A β was deposited in the cortical arterial wall by biopsy, supporting the notion that enlarged PVS is a sign of a blocked drainage pathway by proteins such as A β [25]. Ding and colleagues specifically tested the meningeal lymphatic flow in patients with PD using dynamic contrast-enhanced MRI, and proved significant reduction of lymphatic flow as well as notable delay in deep cervical lymph node perfusion in these patients. In addition, the delayed meningeal lymphatic drainage was followed by α -syn pathology in mice model [8, 22]. This study provided direct evidence of impaired glymphatic system in PD and the consequent neurodegeneration (e.g. α -syn pathology). Therefore, PVS visible on routine MRI may be an alternative a possible way to explore the static glymphatic pathway offline. [26, 27]

In PD patients with higher BG-PVS burden, CSF α -syn, tTau and pTau levels were higher, while the CSF A β_{42} level was lower compared with patients with mild or none BG-PVS. Hypothetically, reduced efflux as a result glymphatic dysfunction should cause increased CSF protein level. As for A β_{42} , it is possible that the decreased CSF A β_{42} reflected more extensive peptide aggregation and plaque formation in brain tissue. [30]. Tau and A β have independent as well as synergistic effects on cognition [26]. In our analysis, the interaction between CSF biomarker and BG-PVS was more predominant for A β_{42} /tTau, and A β_{42} /pTau, compared with A β_{42} alone. It is possible that glymphatic dysfunction blocked CSF toxic proteins, and the interaction between these increased proteins (e.g. Tau-A β_{42} interaction) accelerated the aggregation of amyloid, lowering the amounts of A β_{42} being tested in

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Subscript

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: (Default) Times New Roman, 10 pt

Formatted: Font: 10 pt

CSF.

CSF A β ₄₂, A β ₄₂/tTau, and A β ₄₂/pTau were not specific PD biomarkers. However, emerging evidence suggests that concurrent proteinopathies and their synergistic interactions, are quite common and may contribute to cognitive decline in patients with PD [27]. There might be concomitant AD pathology playing a role in our findings. Previous studies suggested that PVSs in the centrum semiovale and hippocampus were as associated with the diagnosis of AD [28, 29], and PVSs in the hippocampus was associated with hippocampal atrophy [29]. However, the association between PVS visible on MRI and CSF biomarkers was not statistically significant in cognitively impaired individuals in Neurodegenerative Disorders Early and Reliably (BioFINDER) study [29]. More studies are needed to test the association between PVS visible on MRI and CSF biomarkers in demented and non-demented populations.

~~The interactive effect between BG-PVS and CSF A β ₄₂, A β ₄₂/tTau, and A β ₄₂/pTau on cognitive decline was a novel finding in our study. This suggests that modification of the glymphatic pathway may be a potential and crucial therapeutic target to alleviate the pathologic effect of A β ₄₂ and Tau on cognitive decline in PD. Emerging evidence has demonstrated the interaction between PVS and AD-related proteins in animal models [28], and our result further supported the additive consequence of their interaction in human cohort. In addition, the benefit of treatment targeting the glymphatic pathway may be beyond AD-related pathology since PVS has also been highlighted to be involved in the inflammatory process in multiple sclerosis [36]. Sleep intervention may be an effective way to improve glymphatic function, which may need to be tested in clinical trials or observational studies [37]. Other treatments targeting pericytes, endothelial cells, perivascular inflammation and other factors pertaining to glymphatic function also deserve to be investigated.~~

In addition to our initial hypothesis, the factors associated with 3-year cognitive decline were largely consistent with previous 2-year follow-up analysis [16]. More recently, Irwin and colleagues reported that AD-related CSF biomarkers were associated with 3-year cognitive decline in a PPMI cohort [17]. Although finding risk factors associated with cognitive decline was not the main topic of our study, the consistency with previous data suggests that the present data are representative of the whole cohort despite missing BG-PVS data in 59 patients (missing rate = 13.9%).

We acknowledge several limitations. First, this study did not measure the dynamic function of the glymphatic pathway in vivo. Currently, dynamic fluid exchange by the glymphatic pathway has been investigated in vivo by intrathecal injection of the contrast agent in neurological diseases such as idiopathic normal pressure hydrocephalus [6]. These approaches enable tracking uptake and distribution of tracers dynamically, but they are invasive and may not be applicable in patients with PD. Second, although CSF A β ₄₂ and Tau are consistently found to be associated with cognitive decline in PD, they are not PD-specific biomarkers. In addition, the findings of the present study only represent the PD population. Whether proteinaceous waste such as A β and Tau drives the increased visibility of PVS on MRI and potentially mediates its toxicity needs to be tested in the AD population and normal aging population.

In conclusion, we found that BG-PVS may be independently associated with cognitive decline in PD, which may be partially mediated by toxic CSF proteins. The increased visibility of BG-PVS on MRI may reflect more advanced glymphatic dysfunction. PVS may serve as a therapeutic target to preserve cognition in PD.

Conflict of interest

None

Acknowledgements

PPMI is supported by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbott, Avid, Biogen idec, Bristol-Myers Squibb, Covance, Elan, GE Healthcare, Genentech, GSK, Lilly, MERCK, MSD, Pfizer, Roche and UCB (details of the PPMI funding partners found at [www.ppmiinfo.org/ funding partners](http://www.ppmiinfo.org/funding-partners)). Huimin Chen is supported by Beijing Hospital Project (BJ-2021-197). Yilong Wang is supported by grants from the National Natural Science Foundation of China (81825007), the Ministry of Science and Technology of the People's Republic of China (2017YFC1307900), Beijing Outstanding Young Scientist Program (BJJWZYJH01201910025030), the third batch of National Ten Thousand Talents Plan, the Beijing Municipal Science and Technology Commission (Beijing Excellent Talents Training and Supporting Top Youth Team, D171100003017001 and 2016000021223TD03), and the Youth Beijing Scholar Program.

Formatted: Font: (Default) Times New Roman

References:

- [1] S. Hall, Y. Surova, A. Ohrfelt, F.S. Swedish Bio, K. Blennow, H. Zetterberg, O. Hansson, Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease, *Mov Disord* 31(6) (2016) 898-905.
- [2] M. Shahid, J. Kim, K. Leaver, T. Hendershott, D. Zhu, B. Cholerton, V.W. Henderson, L. Tian, K.L. Poston, An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF ~~A β 42~~ and an APOE epsilon4 allele, *Neurobiol Dis* 127 (2019) 278-286.
- [3] M. Delgado-Alvarado, R. Dacosta-Aguayo, I. Navalpotro-Gomez, B. Gago, A. Gorostidi, H.

Formatted: Line spacing: Double

Formatted: Font: (Default) Times New Roman

Formatted: Font: (Default) Times New Roman

Jimenez-Urbieto, A. Quiroga-Varela, J. Ruiz-Martinez, A. Bergareche, M.C. Rodriguez-Oroz, Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study, *Mov Disord* 33(11) (2018) 1809-1813.

[4] E.L. Boespflug, M.J. Simon, E. Leonard, M. Grafe, R. Woltjer, L.C. Silbert, J.A. Kaye, J.J. Iliff, Targeted Assessment of Enlargement of the Perivascular Space in Alzheimer's Disease and Vascular Dementia Subtypes Implicates Astroglial Involvement Specific to Alzheimer's Disease, *J Alzheimers Dis* 66(4) (2018) 1587-1597.

[5] M.K. Rasmussen, H. Mestre, M. Nedergaard, The glymphatic pathway in neurological disorders, *Lancet Neurol* 17(11) (2018) 1016-1024.

[6] M.J. de Leon, Y. Li, N. Okamura, W.H. Tsui, L.A. Saint-Louis, L. Glodzik, R.S. Osorio, J. Fortea, T. Butler, E. Pirraglia, S. Fossati, H.J. Kim, R.O. Carare, M. Nedergaard, H. Benveniste, H. Rusinek, Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET, *J Nucl Med* 58(9) (2017) 1471-1476.

[7] S. Jankeviciute, G. Psemeneckiene, R. Morkuniene, E. Grusauskiene, K. Petrikonis, D. Rastenyte, V. Borutaite, Cerebrospinal fluids from Alzheimer's disease patients exhibit neurotoxic effects on neuronal cell cultures, *Eur J Neurosci* 50(2) (2019) 1994-2006.

[8] X.B. Ding, X.X. Wang, D.H. Xia, H. Liu, H.Y. Tian, Y. Fu, Y.K. Chen, C. Qin, J.Q. Wang, Z. Xiang, Z.X. Zhang, Q.C. Cao, W. Wang, J.Y. Li, E. Wu, B.S. Tang, M.M. Ma, J.F. Teng, X.J. Wang, Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson's disease, *Nat Med* 27(3) (2021) 411-418.

[9] I. Parkinson Progression Marker, The Parkinson Progression Marker Initiative (PPMI), *Prog Neurobiol* 95(4) (2011) 629-35.

- [10] J.M. Wardlaw, E.E. Smith, G.J. Biessels, C. Cordonnier, F. Fazekas, R. Frayne, R.I. Lindley, J.T. O'Brien, F. Barkhof, O.R. Benavente, S.E. Black, C. Brayne, M. Breteler, H. Chabriat, C. Decarli, F.E. de Leeuw, F. Doubal, M. Duering, N.C. Fox, S. Greenberg, V. Hachinski, I. Kilimann, V. Mok, R. Oostenbrugge, L. Pantoni, O. Speck, B.C. Stephan, S. Teipel, A. Viswanathan, D. Werring, C. Chen, C. Smith, M. van Buchem, B. Norrving, P.B. Gorelick, M. Dichgans, S.T.f.R.V.c.o. nEuroimaging, Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration, *Lancet Neurol* 12(8) (2013) 822-38.
- [11] F. Fazekas, R. Kleinert, H. Offenbacher, R. Schmidt, G. Kleinert, F. Payer, H. Radner, H. Lechner, Pathologic correlates of incidental MRI white matter signal hyperintensities, *Neurology* 43(9) (1993) 1683-9.
- [12] F.N. Doubal, A.M. MacLulich, K.J. Ferguson, M.S. Dennis, J.M. Wardlaw, Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease, *Stroke* 41(3) (2010) 450-4.
- [13] G.M. Potter, F.N. Doubal, C.A. Jackson, F.M. Chappell, C.L. Sudlow, M.S. Dennis, J.M. Wardlaw, Enlarged perivascular spaces and cerebral small vessel disease, *Int J Stroke* 10(3) (2015) 376-81.
- [14] J.H. Kang, B. Mollenhauer, C.S. Coffey, J.B. Toledo, D. Weintraub, D.R. Galasko, D.J. Irwin, V. Van Deerlin, A.S. Chen-Plotkin, C. Caspell-Garcia, T. Waligorska, P. Taylor, N. Shah, S. Pan, P. Zero, M. Frasier, K. Marek, K. Kiebertz, D. Jennings, C.M. Tanner, T. Simuni, A. Singleton, A.W. Toga, S. Chowdhury, J.Q. Trojanowski, L.M. Shaw, I. Parkinson's Progression Marker, CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study, *Acta Neuropathol* 131(6) (2016) 935-49.
- [15] B. Mollenhauer, C.J. Caspell-Garcia, C.S. Coffey, P. Taylor, L.M. Shaw, J.Q. Trojanowski, A. Singleton, M. Frasier, K. Marek, D. Galasko, I. Parkinson's Progression Marker, Longitudinal CSF

biomarkers in patients with early Parkinson disease and healthy controls, *Neurology* 89(19) (2017) 1959-1969.

[16] A. Schrag, U.F. Siddiqui, Z. Anastasiou, D. Weintraub, J.M. Schott, Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study, *Lancet Neurol* 16(1) (2017) 66-75.

[17] D.J. Irwin, J. Fedler, C.S. Coffey, C. Caspell-Garcia, J.H. Kang, T. Simuni, T. Foroud, A.W. Toga, C.M. Tanner, K. Kiebertz, L.M. Chahine, A. Reimer, S. Hutten, D. Weintraub, B. Mollenhauer, D.R. Galasko, A. Siderowf, K. Marek, J.Q. Trojanowski, L.M. Shaw, I. Parkinson's Progression Marker, Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease, *Ann Neurol* (2020).

[18] Y.W. Park, N.Y. Shin, S.J. Chung, J. Kim, S.M. Lim, P.H. Lee, S.K. Lee, K.J. Ahn, Magnetic Resonance Imaging-Visible Perivascular Spaces in Basal Ganglia Predict Cognitive Decline in Parkinson's Disease, *Mov Disord* 34(11) (2019) 1672-1679.

[19] J.J. Iliff, M. Wang, D.M. Zeppenfeld, A. Venkataraman, B.A. Plog, Y. Liao, R. Deane, M. Nedergaard, Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain, *J Neurosci* 33(46) (2013) 18190-9.

[20] I. Riba-Llena, J. Jimenez-Balado, X. Castane, A. Girona, A. Lopez-Rueda, X. Mundet, C.I. Jarca, J. Alvarez-Sabin, J. Montaner, P. Delgado, Arterial Stiffness Is Associated With Basal Ganglia Enlarged Perivascular Spaces and Cerebral Small Vessel Disease Load, *Stroke* 49(5) (2018) 1279-1281.

[21] J.M. Wardlaw, H. Benveniste, M. Nedergaard, B.V. Zlokovic, H. Mestre, H. Lee, F.N. Doubal, R. Brown, J. Ramirez, B.J. MacIntosh, A. Tannenbaum, L. Ballerini, R.L. Rungta, D. Boido, M. Sweeney, A. Montagne, S. Charpak, A. Joutel, K.J. Smith, S.E. Black, D. colleagues from the Fondation Leducq

Transatlantic Network of Excellence on the Role of the Perivascular Space in Cerebral Small Vessel, Perivascular spaces in the brain: anatomy, physiology and pathology, *Nat Rev Neurol* 16(3) (2020) 137-153.

[22] E.K. Donahue, A. Murdos, M.W. Jakowec, N. Sheikh-Bahaei, A.W. Toga, G.M. Petzinger, F. Seppehrband, Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease, *Mov Disord* 36(5) (2021) 1126-1136.

[23] Y. Li, Z. Zhu, J. Chen, M. Zhang, Y. Yang, P. Huang, Dilated Perivascular Space in the Midbrain May Reflect Dopamine Neuronal Degeneration in Parkinson's Disease, *Front Aging Neurosci* 12 (2020) 161.

[24] B.L. Sun, L.H. Wang, T. Yang, J.Y. Sun, L.L. Mao, M.F. Yang, H. Yuan, R.A. Colvin, X.Y. Yang, Lymphatic drainage system of the brain: A novel target for intervention of neurological diseases, *Prog Neurobiol* 163-164 (2018) 118-143.

[25] A. Keable, K. Fenna, H.M. Yuen, D.A. Johnston, N.R. Smyth, C. Smith, R. Al-Shahi Salman, N. Samarasekera, J.A. Nicoll, J. Attems, R.N. Kalaria, R.O. Weller, R.O. Carare, Deposition of amyloid beta in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in cerebral amyloid angiopathy, *Biochim Biophys Acta* 1862(5) (2016) 1037-46.

[26] M.A. Busche, B.T. Hyman, Synergy between amyloid-beta and tau in Alzheimer's disease, *Nat Neurosci* 23(10) (2020) 1183-1193.

[27] L. Farotti, F. Paolini Paoletti, S. Simoni, L. Parnetti, Unraveling Pathophysiological Mechanisms of Parkinson's Disease: Contribution of CSF Biomarkers, *Biomark Insights* 15 (2020) 1177271920964077.

[28] G. Banerjee, H.J. Kim, Z. Fox, H.R. Jager, D. Wilson, A. Charidimou, H.K. Na, D.L. Na, S.W. Seo, D.J. Werring, MRI-visible perivascular space location is associated with Alzheimer's disease

independently of amyloid burden, *Brain* 140(4) (2017) 1107-1116.

[29] E.C. Gertje, D. van Westen, C. Panizo, N. Mattsson-Carlgen, O. Hansson, Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease, *Neurology* 96(2) (2021) e193-e202.

Formatted: EndNote Bibliography

Figure legends

Figure 1. Correlation between CSF biomarkers and cognitive outcomes stratified by BG-PVS

BG-PVS modified the effect of $A\beta_{42}/t\text{Tau}$ (A), $A\beta_{42}/p\text{Tau}$ (B), $A\beta_{42}$ (C) on cognitive outcome in Parkinson's disease, as high BG-PVS group showed steeper decline in the MoCA score in relation to CSF biomarkers at the 3-year follow-up.

Abbreviations: BG-PVS, basal-ganglia perivascular space; CSF, cerebrospinal fluid.

Figure 2. Path analysis

~~A~~ CSF $A\beta_{42}/t\text{Tau}$, but not $A\beta_{42}/p\text{Tau}$ or CSF $A\beta_{42}$ significantly mediated the effect of BG-PVS on cognitive decline in patients with PD. ~~The effect of WMH (B) or CS-PVS (C) on cognitive outcome was not mediated by CSF biomarkers.~~

Abbreviations: BG-PVS, basal-ganglia perivascular space; CSF, cerebrospinal fluid; WMH, white matter hyperintensity.

Supplementary figures:

FIG. S1. Correlation between CSF biomarkers

Abbreviations: CSF, cerebrospinal fluid.

FIG. S2. Correlation between CSF biomarkers and cognitive decline stratified by the presence of cardiovascular disease

The presence of cardiovascular disease did not modify the effect of CSF biomarkers on cognitive decline in patients with PD.

FIG. S3. Path analysis for WMH, ~~CS-PVS and CSF biomarker~~lacune, and CS-PVSs

CSF biomarkers did not mediate the effect of WMH, ~~the presence of lacune~~ or CS-PVS on cognitive

decline in PD.

Table 1. Demographic information between groups stratified by BG-PVS

	PD with low BG- PVS (N = 286)	PD with high BG- PVS (N = 55)	P value
<i>Demographic</i>			
Age (median, IQR, year)	60.7 (53.5–66.6)	71.1 (67.1–74.8)	<0.001
Gender (F/M)	100/186	15/40	0.269
<i>Disease profile</i>			
Disease duration (median, IQR, month)	4 (2–7)	6 (3–13)	0.066
MoCA Score (median, IQR)	28 (26–29)	27 (25–29)	0.222
Hoehn-Yahr staging (median, IQR)	2 (1–2)	2 (2–2)	0.001
MDS-UPDRS III total (median, IQR)	19 (14–26)	22 (16–27)	0.024
<u>Tremor subscore (median, IQR)</u>	<u>5 (2–8)</u>	<u>6 (2–9)</u>	<u>0.117</u>
<u>Bradykinesia subscore (median, IQR)</u>	<u>11 (6–15)</u>	<u>14 (9–19)</u>	0.008
<u>Axial subscore (median, IQR)</u>	<u>4 (2–5)</u>	<u>4 (3–7)</u>	0.008
<u>Rigidity subscore (median, IQR)</u>	<u>4 (2–6)</u>	<u>5 (3–9)</u>	0.031
State Trait Anxiety Score (median, IQR)	94 (89–98)	94 (88–97)	0.500
Geriatric Depression Scale (median, IQR)	5 (5–6)	5 (4–6)	0.280
<i>CSF biomarkers</i>			
CSF α -synuclein (median, IQR, pg/ml)	1351.3 (1029.3– 1718.0)	1528.8 (1164.3– 2086.0)	0.016
CSF A β ₄₂ (median, IQR, pg/mL)	848.6 (615.1– 1119.0)	822.2 (627.9– 1050.5)	0.860

Formatted: Font: Not Bold

CSF pTau (median, IQR, pg/mL)	13.0 (10.9–16.7)	15.4 (12.4–21.4)	0.001
CSF tTau (median, IQR, pg/mL)	152.6 (124.0–192.6)	186.4 (147.2–237.7)	<0.001
CSF A β ₄₂ /tTau	5.81 (4.69–6.69)	4.88 (3.71–6.01)	0.002
CSF A β ₄₂ /pTau	69.4 (57.4–80.3)	61.1 (42.7–75.7)	0.002

DAT striatal binding ratios

Mean caudate uptake (median, IQR)	2.02 (1.67–2.37)	1.88 (1.54–2.21)	0.155
Mean putamen uptake (median, IQR)	1.79 (1.48–2.18)	1.77 (1.34–2.08)	0.270
Caudate asymmetry (median, IQR)	1.19 (1.10–1.31)	1.17 (1.07–1.27)	0.216
Putamen asymmetry (median, IQR)	1.45 (1.19–1.76)	1.39 (1.17–1.73)	0.484

Small vessel disease profile

WMH Fazekas score (median, IQR)	2 (1–2)	3 (2–4)	<0.001
<u>The presence of lacunes (N, %)</u>	<u>145 (50.7%)</u>	<u>45 (81.8%)</u>	<u><0.001</u>
Cardiovascular diseases (N, %)	224 (52.1%)	57 (77.0%)	<0.001
Cerebrovascular diseases (N, %) ^a	2 (0.5%)	2 (2.7%)	0.195

Genetic profile

Presence of APOE ϵ 4 allele (N, %)	68 (23.8%)	13 (23.6)	0.982
---	------------	-----------	-------

Cognition at 3-year follow-up

Change in MoCA score (median, IQR)	0 (-2–1)	-2 (-5–0.25)	0.004
Cognitive impairment (N, %)	46 (18.9)	22 (48.9%)	<0.001

^aCorrection for continuity was adapted for inadequate event.

Formatted Table

Abbreviations: CSF, cerebrospinal fluid; DAT, dopaminergic transporter; IQR, interquartile range;

MDS-UPDRS III, Movement Disorder Society Unified Parkinson's Disease Rating Score part III;

MoCA, Montreal Cognitive Assessment.

Table 2. Linear mixed model for interactive effect of CSF markers and BG-PVS on cognitive outcomes

	MoCA score at 3-year follow-up				Change in MoCA from baseline to 3-year follow-up			
	Model without interaction		Model with interaction		Model without interaction		Model with interaction	
	Coefficient	P value	Coefficient	P value	Coefficient	P value	Coefficient	P value
Model 1								
Baseline A β ₄₂ /tTau	0.385 (0.154-0.617)	0.001	1.087 (0.650-1.524)	<0.001	0.388 (0.156-0.619)	0.001	1.086 (0.649-1.523)	<0.001
BG-PVS \geq 2	REF		REF		REF		REF	
BG-PVS<2	1.302 (0.271-2.334)	0.014	6.364 (3.515-9.214)	<0.001	1.317 (0.285-2.349)	0.013	6.357 (3.507-9.207)	<0.001
A β ₄₂ /tTau*BG-PVS	/		-0.953 (-1.460-)	<0.001	/		-0.949 (-1.456--0.441)	<0.001

Formatted Table

interaction			<u>0.445</u>	0.911 (-1.420)				<u>0.907</u>	(-1.416 - 0.397)
				0.400)					
AIC	<u>823.48</u>	815.5	<u>811.48</u>	804.5	<u>823.28</u>	817.3	<u>811.38</u>	806.3	
Model 2									
Baseline A β_{42} /pTau	<u>0.031</u>	(0.011-0.050)	<u>0.031</u>	0.031	<u>0.002</u>	0.002	<u>0.095</u>	(0.059-	<u><0.001</u>
		0.050)						0.131)	<u><0.001</u>
								0.092 (-0.056-	<u>0.030 (-0.011-</u>
								0.129)	<u>0.131)</u>
								0.050)	<u>0.093 (-0.056-</u>
								0.129)	<u>0.129)</u>
BG-PVS \geq 2	<u>REF</u>	REF	<u>REF</u>	REF	<u>REF</u>	REF	<u>REF</u>	REF	<u>REF</u>
BG-PVS<2	<u>1.364</u>	(0.282-2.445)	<u>1.309</u>	1.309	<u>0.014</u>	0.014	<u>7.040</u>	(4.170-	<u><0.001</u>
		0.267 - 2.350)						9.909)	<u><0.001</u>
								6.580 (-3.740-	<u>1.359 (-0.317-</u>
								9.419)	<u>2.468)</u>
								2.400)	<u>1.359 (-0.317-</u>
								9.441)	<u>9.927)</u>
A β_{42} /pTau*BG-PVS	<u>/</u>	/	<u>/</u>	/	<u><0.001</u>	<0.001	<u>/</u>	(-0.130-	<u><0.001</u>
								-0.088 (-0.130-	<u>(-0.130-</u>
								-0.088 (-0.130-	<u>(-0.130-</u>
interaction			<u>0.046</u>	0.08 (-0.13-				<u>0.084</u>	(-0.126 - 0.042)

Formatted: Font: (Default) Times New Roman

AIC	<u>782.6774.7</u>	<u>765.8772.5</u>	<u>782.4776.4</u>	<u>772.3767.5</u>
Model 3				
Baseline A β_{42}	<u>0.001 (0-0.002)0.001-</u> <u>(-0.000-0.002)</u>	<u>0.0330.035</u>	<u>0.003 (0.001--</u> <u>0.005)0.003 (-0.001-</u> <u>0.005)</u>	<u>0.0030.004</u>
BG-PVS \geq 2	<u>REFREF</u>	<u>REFREF</u>	<u>REF</u>	<u>REFREF</u>
BG-PVS<2	<u>1.286 (0.253-2.318)1.258-</u> <u>(-0.252-2.263)</u>	<u>0.0150.015</u>	<u>3.328 (1.224-</u> <u>5.432)3.184 (-1.084-</u> <u>5.285)</u>	<u>0.0020.003</u>
A β_{42} *BG-PVS interaction	<u>/</u>	<u>-0.002 (-0.004-0)-</u> <u>0.002 (-0.004-0.000)</u>	<u>0.0290.039</u>	<u>/</u>
AIC	<u>867.6859.9</u>	<u>867.874.8.5</u>	<u>867.9861.5</u>	<u>875.2868.9</u>

CSF biomarkers ($A\beta_{42}$, $A\beta_{42}/t\text{Tau}$, $A\beta_{42}/p\text{Tau}$), BG-PVS and their interaction were fixed effect; age, baseline MoCA score, axial subscore of MDS-UPDRS III, RBDSQ, UPSIT, and putamen asymmetry, WMH Fazekas score, the presence of lacunes, past history cardiovascular diseases were set as random effect. ~~CSF biomarkers ($A\beta_{42}$, $A\beta_{42}/t\text{Tau}$, $A\beta_{42}/p\text{Tau}$), BG-PVS and their interaction were fixed effect. Age, baseline MoCA score, RBDSQ, and DAT-putamen asymmetry were set as random effect for MoCA score at 3 year follow up, and baseline state trait anxiety inventory was additionally set as random effect for 3 year change in MoCA; Abbreviations: AIC, Akaike information criterion; BG-PVS, basal ganglia perivascular space; REF, reference.~~

1 **Perivascular Space in Parkinson's Disease: Association with CSF Amyloid/Tau and Cognitive**

2
3 **Decline**

4
5
6 Huimin Chen^{a,b,c,d}, Huijuan Wan^{b,c,d,e}, Meimei Zhang^{b,c,d}, Joanna M Wardlaw^f, Tao Feng^{b,c,d}, Yilong
7
8
9 Wang^{b,c,d}

10
11 ^aDepartment of Neurology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Medicine, Chinese Academy of Medical Sciences, Beijing, China

^bDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

^cChina National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing, China

^dAdvanced Innovation Center for Human Brain Projection, Capital Medical University, Beijing, China

^eDepartment of Neurology, First Affiliated Hospital, Xiamen University, Xiamen, China

^fCentre for Clinical Brain Sciences, UK Dementia Research Institute, University of Edinburgh,
Edinburgh, UK

Corresponding author:

Yilong Wang*, MD, PhD.

Address: China National Clinical Research Center for Neurological Diseases, Beijing Tiantan

Hospital, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing,

China. 100070.

E-mail: yilong528@gmail.com, Tel: +86-139-1166-6571;

Keywords/Search terms: Parkinson's disease; Perivascular Space; Cognition; Amyloid; Tau

Title: 97 characteristics; Tables: 2; Figures:2; supplementary table: 4; supplementary figure 3;

supplementary result:1; Reference:29;

Word count: abstract 249; body of the manuscript 3308;

1 **Abstract**
2

3 **Objective:** Whether perivascular space (PVS) visible on magnetic resonance imaging (MRI) represents
4
5
6 glymphatic dysfunction and whether this imaging marker is pathologic in Parkinson's disease (PD)
7
8
9 have been controversial. The objective was to determine whether PVS visible on MRI is independently
10
11
12 associated with cognitive decline in patients with PD, and to test whether pathologic proteins in the
13
14 CSF (such as $A\beta_{42}$) mediate the pathologic role of PVS.
15

16 **Methods:** A total of 341 patients with Parkinson's disease from Parkinson's Progression Marker
17
18 Initiative (PPMI) cohort was included in the present study. PVS in the basal ganglia (BG-PVS) and
19
20 centrum semiovale were evaluated with a semiquantitative scale. Changes in the Montreal Cognitive
21
22 Assessment (MoCA) score and the absolute MoCA score at the 3-year assessment were considered the
23
24 main cognitive outcome. A multivariable linear regression model was used to test the association
25
26 between PVS and cognitive decline. A mixed linear model and path analysis were used to test the
27
28 interaction among PVS, CSF biomarkers and cognitive decline.
29
30
31
32
33
34

35 **Results:** BG-PVS was associated with cognitive decline in patients with PD at the 3-year follow-up
36
37 independent of age, baseline cognition, motor and nonmotor function, presynaptic dopaminergic
38
39 deficiency, and CSF biomarkers. The interaction between BG-PVS and $A\beta_{42}/t\text{Tau}$, $A\beta_{42}/p\text{Tau}$, and $A\beta_{42}$
40
41 levels was significantly predictive of 3-year cognitive decline. Path analysis confirmed that CSF
42
43 $A\beta_{42}/t\text{Tau}$ levels partially mediated the pathologic effect of BG-PVS on cognitive outcome in PD.
44
45
46
47
48
49

50 **Conclusions:** BG-PVS is independently associated with cognitive decline in PD, and this association
51
52 may be partially mediated by toxic CSF proteins.
53
54

55 **Keywords:** Parkinson's disease; Perivascular Space; Cognition; Amyloid; Tau
56
57
58
59
60
61
62
63
64
65

1. Introduction

Parkinson's disease (PD) is the second most common neurodegenerative disease, with α -synuclein (α -syn) aggregation and Lewy body deposition being the pathologic hallmarks. Previous studies from several cohorts consistently reported that Alzheimer's disease (AD)-related CSF biomarkers (i.e., lower levels of $A\beta_{42}$ and $A\beta_{42}/\text{Tau}$ ratios and higher levels of total and phosphorylated Tau) were associated with cognitive impairment in PD [1-3].

Emerging evidence has highlighted the role of the perivascular space (PVS) as a glymphatic pathway for waste clearance in the brain and demonstrated that glymphatic dysfunction reduced cerebrospinal fluid (CSF) clearance of $A\beta$ in AD models and in patients with AD [4-6]. Since AD-related proteins are toxic to neurons and glial cells [7] and are associated with cognitive decline in AD and PD [1-3], it is possible that reduced CSF clearance of toxic proteins as a result of glymphatic dysfunction may aggregate the neurodegenerative process and facilitate the development of dementia. Indeed, patients with PD showed impaired meningeal lymphatic drainage assessed by dynamic contrast-enhanced magnetic resonance imaging (MRI), which may facilitate the α -syn deposition and result in motor dysfunction in PD mice model [8]. If BG-PVS visible on MRI reflects glymphatic dysfunction, there might be an association between the severity of BG-PVS visible on MRI and higher neurodegenerative burden measured by CSF biomarkers such as $A\beta$.

The Parkinson's Progression Marker Initiative (PPMI) is the largest ongoing cohort of PD with comprehensive clinical, imaging and CSF biomarker data. The PPMI provides an opportunity to confirm the pathologic role of BG-PVS in PD cognitive outcome. In addition, it provides superb data to test the relationship between PVS visible on MRI and neurodegenerative burden measured by CSF biomarkers, which may inform the mechanism and potential therapeutic target of PVS in progressive neurodegenerative processes. In the current analysis of PPMI data, we hypothesized that BG-PVS may

1 be related with cognitive decline in PD, which may be mediated by CSF neurodegenerative
2
3 biomarkers.
4
5
6
7

8 **2. Method**

9 **2.1 Study design and participants**

10
11 PPMI is an ongoing, multicenter, longitudinal, observational study that started in 2010
12
13 (<https://www.ppmi-info.org/>). Patients with early, drug-naïve PD and intact cognition were included.
14
15
16

17
18 The PPMI study was approved by the institutional review board at each site, and participants provided
19
20 written informed consent to participate. The protocol and more detailed study design of PPMI has been
21
22 described elsewhere [9]. From the whole PPMI cohort, only PD patients with complete baseline BG-
23
24 PVS profiles and CSF biomarkers were included in the present analysis. The data used in the current
25
26 study were downloaded from the PPMI dataset in June 2020.
27
28
29
30
31

32 **2.2 Outcome measurements**

33
34 Cognitive decline was evaluated using the change in the MoCA score from baseline to 3-year follow-
35
36 up and the absolute MoCA score at the 3-year assessment. Motor function was measured using the
37
38 Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III and
39
40 Hoehn-Yahr stage. The MDS-UPDRS III score was further divided into four subscores according to the
41
42 cardinal motor symptoms in PD: tremor (items 15-18), bradykinesia (items 4-8, and item14), rigidity
43
44 (item 3), and axial signs (items 1, 2, 9-13). Nonmotor symptoms in the prediction of cognitive decline
45
46 in PD included rapid eye movement behavior disorder (RBD), which was assessed with the RBD
47
48 Screening Questionnaire (RBDSQ); sense of smell, which was assessed with the University of
49
50 Pennsylvania Smell Identification Test (UPSIT); depression, which was assessed with the 15-item
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Geriatric Depression Scale (GDS); and anxiety, which was assessed with the State-Trait Anxiety
2
3 Inventory.
4
5

6 7 **2.3 DAT imaging**

8
9
10 [123I]β-CIT DAT single-photon emission computed tomography (SPECT) imaging was acquired at
11
12 PPMI imaging centers in accordance with the PPMI imaging protocol. Mean caudate and putaminal
13
14 uptake relative to uptake in the occipital area and asymmetry of caudate and putaminal uptake (side
15
16 with highest divided by side with lowest uptake) were computed for the analysis.
17
18
19
20
21

22 **2.4 History of cardio- and cerebrovascular diseases and risk factors**

23
24
25 Histories of cardio- and cerebrovascular diseases were recorded in the PPMI cohort at patient
26
27 screening. Cardiovascular diseases include a history of diabetes, hypertension, hyperlipidemia,
28
29 hypercholesterolemia, and cardiac diseases. Cerebrovascular diseases included a history of
30
31 cerebrovascular accident, transient ischemic attack, ischemic stroke, cervical and carotid stenosis or
32
33 occlusion.
34
35
36
37
38
39

40 **2.5 Imaging markers of cerebral small vessel disease**

41
42
43 Imaging markers of cerebral small vessel disease (CSVD) were evaluated by a neurologist who was
44
45 blind to the patient information (HJ Wan) following the instruction and definition of Standards for
46
47 ReportIng Vascular changes on nEuroimaging (STRIVE) [10]. White matter hyperintensity (WMH)
48
49 was rated according to the Fazekas rating scale [11]. Perivascular space was defined on MRI as small,
50
51 sharply delineated structures of CSF intensity (or close to CSF intensity) following the course of
52
53 perforating vessels. PVS in the basal ganglia and centrum semiovale (CS-PVS) were rated separately
54
55 on T2 weighted sequence as 0 = none, 1 = 1–10, 2 = 11–20, 3 = 21–40, and 4 = >40 PVS per side, and
56
57
58
59
60
61
62
63
64
65

1 the worse side was used if there was asymmetry [12, 13]. In the statistical analysis for BG-PVS,
2
3 patients were stratified into groups with moderate-to-severe BG-PVS (BG-PVS rating \geq 2) and none-to-
4
5 mild BG-PVS (BG-PVS rating $<$ 2). Similarly, in the analysis for WMH and CS-PVS, patients were also
6
7 grouped into the high WMH group (Fazekas $>$ 2) versus the low WMH group (Fazekas \leq 2) and the high
8
9 CS-PVS group (CS-PVS rating \geq 2) versus the low CS-PVS group (CS-PVS rating $<$ 2). This
10
11 stratification was consistent with the distribution of CSVD profiles in our data and was consistent with
12
13 studies showing that BG-PVS rating \geq 2 (moderate to severe) was predictive of unfavorable outcomes
14
15
16
17
18
19
20 [12, 13].
21

22 **2.6 Genotyping**

23
24
25 At the screening visit, genomic DNA was extracted from whole blood of the subject. The APOE
26
27 genotype was analyzed at the PPMI genetic core as previously described [14]. Subjects were classified
28
29
30 by the presence or absence of *APOE* ϵ 4 genotypes.
31

32 **2.7 CSF biomarkers**

33
34
35 The concentration of α -synuclein in CSF samples was analyzed using an ELISA assay available
36
37 commercially from BioLegend. CSF A β ₄₂, total tau (tTau) and tau phosphorylated at the threonine 181
38
39 position (pTau) were analyzed at Biorepository Core laboratories to the University of Pennsylvania
40
41 using Elecsys electrochemiluminescence immunoassays (Roche Diagnostics). More detail and primary
42
43
44 results of the measured CSF biomarkers have been reported previously in the PPMI cohort [14, 15].
45
46
47
48
49

50 **2.8 Statistics**

51
52
53 Continuous variables were compared between groups using the Mann-Whitney test (nonnormal
54
55 distribution) or two sample t test (normal distribution), and categorical variables were compared
56
57
58 between groups using the Chi-square test. Univariable and multivariable linear regression models were
59
60
61

1 performed using the MoCA score at the 3-year follow-up and the 3-year change in the MoCA score as
2
3 separate dependent variables. The regression models consulted a previous PPMI study using 2-year
4
5 cognitive outcomes [16]. Multivariable regression models were conducted with adjustment of variables
6
7 showing a significant association ($p < 0.05$) in the univariable regression analysis (only one significant
8
9 variable of the same feature with lower P value was selected to avoid collinearity), and variables that
10
11 showed significantly unbalanced features between BG-PVS groups. As CSF biomarkers were
12
13 significantly correlated with each other (supplementary figure 1)[17], each biomarker entered the
14
15 multivariable regression model separately.
16
17
18
19
20
21

22 The interaction between BG-PVS and CSF biomarkers in relation to cognition was firstly explored
23
24 by plotting the fitting curve and then by linear mixed models. The change in MoCA score and MoCA
25
26 score at the 3-year follow-up was used as dependent variables in linear mixed models. BG-PVS
27
28 severity and CSF biomarker with or without interaction term were set as fixed effects, and other
29
30 variables showing significant association with cognitive outcomes in univariable regression or
31
32 unbalanced features between BG-PVS groups were used as random effects. The Akaike information
33
34 criterion (AIC) of models with and without the BG-PVS*CSF biomarker interaction item was
35
36 recorded. Path analysis was conducted to investigate how much CSF biomarkers mediated the effect of
37
38 BG-PVS on cognition in PD. The standardized coefficient (β) of BG-PVS without a mediation effect
39
40 (direct effect) and with a mediation effect (indirect effect) and the standardized coefficient (β) of the
41
42 CSF biomarker on the change in MoCA were calculated. P value < 0.05 was defined as significant.
43
44
45
46
47
48
49
50
51
52 Group comparison of CSF biomarkers at each follow-up point was also performed between PD groups
53
54 with different BG-PVS severities. P value < 0.01 was defined as significant in this group comparison
55
56 for multiple comparison correction (correction for 4 repeated comparisons for each CSF biomarker).
57
58
59
60
61
62
63
64
65

1 Group comparison was conducted in SPSS 25.0 (SPSS, inc., Beijing, China), and linear regression and
2
3 linear mixed models were performed in R software version 4.02 (<https://www.r-project.org/>).
4
5

6 To rule out confounding by WMH and lacune, and to investigate the location specificity of PVS,
7
8 their relationships (WMH, the presence of lacune or CS-PVS) with CSF biomarkers and cognitive
9
10 decline were further explored using a similar statistical approach.
11
12

13 ***2.9 Data Availability Statement***

14 The data was publicly available on PPMI website (<https://www.ppmi-info.org/access-data-specimens/>).
15
16
17
18
19
20
21

22 **3. Results**

23 ***3.1 Baseline features of the included patients***

24
25 Four hundred and twenty-three patients with drug-naïve PD were recruited in PPMI cohort. Among
26
27 these subjects, MRI imaging or T2-weighted imaging was missing in 47 patients, and imaging in
28
29 another 13 patients was not qualified to rate BG-PVS due to incomplete or nonaxial slices. CSF
30
31 biomarkers were missing in another 22 patients with PD. Finally, 341 patients with complete baseline
32
33 PVS and CSF biomarkers were included in the present analysis. The included and excluded patients
34
35 showed overall similar demographic and behavioral profiles (supplementary table 1).
36
37
38
39
40
41
42
43

44 ***3.2 Group comparison between patients with lower and higher BG-PVS burdens***

45
46 Compared with patients with lower BG-PVS burden, patients with more severe BG-PVS were
47
48 significantly older; had more impaired motor function at baseline; had a higher prevalence of previous
49
50 cardiovascular disease; had a higher prevalence of lacune presence and more severe WMH at baseline;
51
52 had a higher risk of cognitive impairment and a greater decline in the MoCA score at the 3-year follow-
53
54 up despite of similar baseline MoCA scores; and showed lower levels of CSF $A\beta_{42}$, $A\beta_{42}/t\text{Tau}$,
55
56
57
58
59
60
61
62

1 $A\beta_{42}/p\text{Tau}$ and higher levels of CSF $\alpha\text{-syn}$, $t\text{Tau}$ and $p\text{Tau}$ at baseline (**Table 1**).

2 3 4 **3.3 Univariable linear regression for cognition at the 3-year follow-up**

5
6 Using the absolute MoCA score at the 3-year follow-up as the dependent variable, age, baseline MoCA
7
8 score, MDS-UPDRS III total score, tremor, bradykinesia, and axial subscores, RBDSQ, UPSIT score,
9
10 CSF $A\beta_{42}$, $t\text{Tau}$, $p\text{Tau}$, $A\beta_{42}/t\text{Tau}$, $A\beta_{42}/p\text{Tau}$, putamen asymmetry and BG-PVS were significantly
11
12 associated with cognition at the 3-year follow-up in PD patients ($P<0.05$).

13
14
15
16
17 Using decline in MoCA score as the dependent variable, age, baseline MoCA score, RBDSQ,
18
19
20 UPSIT score, axial subscore of MDS-UPDRS III, CSF $A\beta_{42}$, $t\text{Tau}$, $p\text{Tau}$, $A\beta_{42}/t\text{Tau}$, $A\beta_{42}/p\text{Tau}$,
21
22 putamen asymmetry, and BG-PVS were significantly associated with cognitive decline during three
23
24 years in PD patients ($P<0.05$) (supplementary table 2).

25 26 27 28 **3.4 Multivariable linear regression for cognition at the 3-year follow-up**

29
30
31 In multivariable regression models, BG-PVS was significantly associated with MoCA score or
32
33 change in MoCA score, independent of age, past-history cardiovascular diseases, baseline MoCA score,
34
35 axial subscore of MDS-UPDRS III, RBDSQ, UPSIT, putamen asymmetry, WMH Fazekas score, the
36
37 presence of lacune, and CSF biomarkers. Baseline CSF $A\beta_{42}$, $A\beta_{42}/t\text{Tau}$ and $A\beta_{42}/p\text{Tau}$ were
38
39 significantly associated with the MoCA score or change in the MoCA score at 3-year follow-up
40
41 independent of age, past-history cardiovascular diseases, baseline MoCA score, axial subscore of
42
43 MDS-UPDRS III, RBDSQ, UPSIT, putamen asymmetry, WMH Fazekas score, the presence of lacune,
44
45 and BG-PVS. However, baseline CSF $t\text{Tau}$ and $p\text{Tau}$ were not significantly associated with either
46
47
48
49
50
51
52
53 cognitive outcome at year three after adjustment (supplementary table 3).

54 55 56 **3.5 Interaction between CSF biomarkers and BG-PVS**

57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1 interactions between BG-PVS and these CSF biomarkers (**Table 2**), such that patients with higher BG-
2
3 PVS and lower A β_{42} /tTau (**Figure 1A**), A β_{42} /pTau (**Figure 1B**), or A β_{42} (**Figure 1C**) showed steeper
4
5 decline in the MoCA score at the 3-year follow-up. Models containing interaction terms provided a
6
7 slightly improved fit. As patients with a higher BG-PVS burden had a higher prevalence of
8
9 cardiovascular disease, we further tested whether the interaction between BG-PVS and CSF biomarkers
10
11 was confounded by the presence of cardiovascular disease. However, the correlation between CSF
12
13 biomarkers and cognitive decline was not stratified by the presence of cardiovascular disease
14
15 (supplementary figure 2).
16
17
18
19
20
21

22 We further compared CSF biomarkers at each follow-up timepoint between the BG-PVS groups.
23
24 The results revealed that patients with more severe BG-PVS showed significantly higher levels of all
25
26 measured CSF biomarkers at baseline, 1-year follow-up, and 2-year follow-up, and the significant
27
28 difference in tTau and pTau was still observed at year three with corrected P values ($P < 0.01$)
29
30 (supplementary table 4).
31
32
33
34
35

36 *3.6 Path analysis*

37
38 In path analysis, CSF A β_{42} /tTau was found to mediate the effect of BG-PVS on cognitive decline (total
39
40 effect [original coefficient] = -0.256, direct effect [corrected coefficient] = -0.208, indirect effect = -
41
42 0.048) (**Figure 2A**). That is, CSF A β_{42} /tTau mediated 18.8% (indirect effect/total effect) of the BG-
43
44 PVS effect on the decrease in MoCA scores during the 3-year follow-up. In path analysis, the
45
46 correlation of BG-PVS with A β_{42} /pTau was marginally significant, and that with A β_{42} was not
47
48 significant (**Figure 2B and 2C**).
49
50
51
52
53
54

55 *3.7 Additional analysis with WMH and CS-PVS*

56
57 To rule out the confounding effect of WMH, lacune and CS-PVS, additional analysis was performed.
58
59
60
61
62
63
64
65

1 No significant association was found among WMH, CSF biomarkers, and cognitive outcome; among
2
3 the presence of lacune, CSF biomarkers, and cognitive outcome; and among CS-PVS, CSF biomarkers,
4
5 and cognitive outcome (see supplementary figure 3 and supplementary result).
6
7
8
9

10 11 **4. Discussion**

12
13 This is the first study that examined the relationship among CSF biomarkers, cognitive outcome and
14
15 PVS visible on MRI in PD. The main finding demonstrated that BG-PVS was independently associated
16
17 with cognitive decline in patients with PD. In addition, BG-PVS modified the pathologic effect of
18
19 $A\beta_{42}/t\text{Tau}$, $A\beta_{42}/p\text{Tau}$, and $A\beta_{42}$ on cognitive decline in PD. Path analysis confirmed that CSF
20
21 biomarkers, especially $A\beta_{42}/t\text{Tau}$, partially mediated the pathologic effect of BG-PVS on cognitive
22
23 outcomes in PD. These results suggest that the increased visibility of BG-PVS on MRI may reflect
24
25 more advanced glymphatic dysfunction, resulting in higher levels of toxic CSF proteins, which may in
26
27 turn accelerate neurodegenerative processes and cognitive decline. It also implies that the glymphatic
28
29 pathway may serve as a therapeutic target to preserve cognition in neurodegenerative disease.
30
31
32
33
34
35
36
37
38

39 Our results validated a previous study by Park and colleagues [18], and showed that BG-PVS was
40
41 associated with 3-year cognitive decline in patients with PD. In addition, the contribution to poor
42
43 cognitive outcome and the interaction with CSF proteins were specific for PVS located in the basal
44
45 ganglia but not the centrum semiovale. However, the underlying mechanism for the location specificity
46
47 remains unclear. Evidence suggests that cerebral arterial pulsation drove CSF-interstitial fluid exchange
48
49 mediated by the glymphatic pathway [19], and arterial stiffness was associated with a higher BG-PVS
50
51 burden [20]. It is possible that PVS in the basal ganglia may be more prone to arterial damage and
52
53 pulsation change during aging. However, we did not test arterial function, such as arterial stiffness and
54
55
56
57
58
59
60
61
62
63
64
65

1 regulation. Future studies will be needed to test this hypothesis. In addition, BG-PVS differs from CS-
2
3 PVS in structure, as BG-PVS is covered by two leptomeningeal membranes and directly connects CSF
4
5
6 [21]. This means that BG-PVS may be more active in eliminating waste from CSF, and the increased
7
8
9 visibility of BG-PVS may represent an increased effort in waste clearance. Future studies directly
10
11
12 comparing CSF dynamics are needed to investigate the location difference of PVS.

13
14 Moreover, the results suggested that PVS visible on MRI may reflect glymphatic dysfunction,
15
16
17 impaired efflux of CSF proteins and more advanced neurodegeneration in patients with PD. Previous
18
19
20 evidence suggested that patients with PD showed higher volume fraction of PVS, especially for those
21
22
23 familial patients with genetic mutation [22]. Previous PPMI data also suggested that PVS in midbrain
24
25
26 was associated neurodegenerative imaging marker (DAT deficiency) [23]. These findings support our
27
28
29 hypothesis that PVS visible on MRI may be closely linked with neurodegeneration in patients with PD.
30
31
32 We found that the level of neurodegenerative CSF proteins ($A\beta_{42}/tTau$) partially mediated the effect of
33
34
35 BG-PVS on poor cognitive outcome. Taking that CSF proteins, including $A\beta$ and Tau, are toxic to
36
37
38 neurons and glial cells [7] and AD biomarkers are predictive of cognitive decline in PD [1-3], the result
39
40
41 implies that BG-PVS may contribute to cognitive decline by elevating toxic CSF proteins in patients
42
43
44 with PD.

45
46
47 The glymphatic pathway has drawn much attention in recent years as a novel pathway to exclude
48
49
50 neurotoxic proteins and a potential therapeutic target [24]. In patients with superficial sclerosis, PVS
51
52
53 was enlarged beneath the affected area where $A\beta$ was deposited in the cortical arterial wall by biopsy,
54
55
56 supporting the notion that enlarged PVS is a sign of a blocked drainage pathway by proteins such as $A\beta$
57
58
59 [25]. Ding and colleagues specifically tested the meningeal lymphatic flow in patients with PD using
60
61
62 dynamic contrast-enhanced MRI, and proved significant reduction of lymphatic flow as well as notable
63
64
65

1 delay in deep cervical lymph node perfusion in these patients. In addition, the delayed meningeal
2
3 lymphatic drainage was followed by α -syn pathology in mice model [8, 22]. This study provided
4
5 direct evidence of impaired glymphatic system in PD and the consequent neurodegeneration (e.g. α -syn
6
7 pathology). PVS visible on routine MRI may be an alternative way to explore the static glymphatic
8
9 pathway offline.
10
11
12

13
14 In PD patients with higher BG-PVS burden, the CSF $A\beta_{42}$ level was lower compared with patients
15
16 with mild or none BG-PVS. Hypothetically, reduced efflux as a result glymphatic dysfunction should
17
18 cause increased CSF protein level. As for $A\beta_{42}$, it is possible that the decreased CSF $A\beta_{42}$ reflected
19
20 more extensive peptide aggregation and plaque formation in brain tissue. Tau and $A\beta$ have independent
21
22 as well as synergistic effects on cognition [26]. In our analysis, the interaction between CSF biomarker
23
24 and BG-PVS was more predominant for $A\beta_{42}/t\text{Tau}$, and $A\beta_{42}/p\text{Tau}$, compared with $A\beta_{42}$ alone. It is
25
26 possible that glymphatic dysfunction blocked CSF toxic proteins, and the interaction between these
27
28 increased proteins (e.g. Tau- $A\beta_{42}$ interaction) accelerated the aggregation of amyloid, lowering the
29
30 amounts of $A\beta_{42}$ being tested in CSF.
31
32
33
34
35
36
37
38

39 CSF $A\beta_{42}$, $A\beta_{42}/t\text{Tau}$, and $A\beta_{42}/p\text{Tau}$ were not specific PD biomarkers. However, concurrent
40
41 proteinopathies and their synergistic interactions are quite common and may contribute to cognitive
42
43 decline in patients with PD [27]. There might be concomitant AD pathology playing a role in our
44
45 findings. Previous studies suggested that PVS in the centrum semiovale and hippocampus was
46
47 associated with the diagnosis of AD [28, 29], and PVS in the hippocampus was associated with
48
49 hippocampal atrophy[29]. However, the association between PVS visible on MRI and CSF biomarkers
50
51 was not statistically significant in cognitively impaired individuals in Neurodegenerative Disorders
52
53 Early and Reliably (BioFINDER) study [29]. More studies are needed to test the association between
54
55
56
57
58
59
60
61
62
63
64
65

1 PVS visible on MRI and CSF biomarkers in demented and non-demented populations.
2

3 In addition to our initial hypothesis, the factors associated with 3-year cognitive decline were
4 largely consistent with previous 2-year follow-up analysis [16]. More recently, Irwin and colleagues
5 reported that AD-related CSF biomarkers were associated with 3-year cognitive decline in a PPMI
6 cohort [17]. Although finding risk factors associated with cognitive decline was not the main topic of
7 our study, the consistency with previous data suggests that the present data are representative of the
8 whole cohort despite missing BG-PVS data in 59 patients (missing rate = 13.9%).
9
10
11
12
13
14
15
16
17
18
19

20 We acknowledge several limitations. First, this study did not measure the dynamic function of the
21 glymphatic pathway in vivo. Currently, dynamic fluid exchange by the glymphatic pathway has been
22 investigated in vivo by intrathecal injection of the contrast agent in neurological diseases such as
23 idiopathic normal pressure hydrocephalus [6]. These approaches enable tracking uptake and
24 distribution of tracers dynamically, but they are invasive and may not be applicable in patients with PD.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

66 In conclusion, we found that BG-PVS may be independently associated with cognitive decline in
67 PD, which may be partially mediated by toxic CSF proteins. The increased visibility of BG-PVS on
68 MRI may reflect more advanced glymphatic dysfunction. PVS may serve as a therapeutic target to
69 preserve cognition in PD.
70

1 **Conflict of interest**

2
3 None

4
5
6
7
8
9 **Acknowledgements**

10
11 PPMI is supported by the Michael J. Fox Foundation for Parkinson's Research and funding partners,
12 including Abbott, Avid, Biogen idec, Bristol-Myers Squibb, Covance, Elan, GE Healthcare, Genentech,
13 GSK, Lilly, MERCK, MSD, Pfizer, Roche and UCB (details of the PPMI funding partners found at
14 www.ppmiinfo.org/ funding partners). Huimin Chen is supported by Beijing Hospital Project (BJ-2021-
15 197). Yilong Wang is supported by grants from the National Natural Science Foundation of China
16 (81825007), the Ministry of Science and Technology of the People's Republic of China
17 (2017YFC1307900), Beijing Outstanding Young Scientist Program (BJJWZYJH01201910025030), the
18 third batch of National Ten Thousand Talents Plan, the Beijing Municipal Science and Technology
19 Commission (Beijing Excellent Talents Training and Supporting Top Youth Team, D171100003017001
20 and 2016000021223TD03), and the Youth Beijing Scholar Program.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **References:**

- 43
44 [1] S. Hall, Y. Surova, A. Ohrfelt, F.S. Swedish Bio, K. Blennow, H. Zetterberg, O. Hansson,
45 Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease, *Mov Disord* 31(6)
46 (2016) 898-905.
47
48 [2] M. Shahid, J. Kim, K. Leaver, T. Hendershott, D. Zhu, B. Cholerton, V.W. Henderson, L. Tian, K.L.
49 Poston, An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients
50 with low CSF A β 42 and an APOE epsilon4 allele, *Neurobiol Dis* 127 (2019) 278-286.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 [3] M. Delgado-Alvarado, R. Dacosta-Aguayo, I. Navalpotro-Gomez, B. Gago, A. Gorostidi, H.
2
3 Jimenez-Urbieta, A. Quiroga-Varela, J. Ruiz-Martinez, A. Bergareche, M.C. Rodriguez-Oroz, Ratios of
4
5 proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study, *Mov Disord*
6
7 33(11) (2018) 1809-1813.
8
9
- 10 [4] E.L. Boespflug, M.J. Simon, E. Leonard, M. Grafe, R. Woltjer, L.C. Silbert, J.A. Kaye, J.J. Iliff,
11
12 Targeted Assessment of Enlargement of the Perivascular Space in Alzheimer's Disease and Vascular
13
14 Dementia Subtypes Implicates Astroglial Involvement Specific to Alzheimer's Disease, *J Alzheimers Dis*
15
16 66(4) (2018) 1587-1597.
17
18
- 19 [5] M.K. Rasmussen, H. Mestre, M. Nedergaard, The glymphatic pathway in neurological disorders,
20
21 *Lancet Neurol* 17(11) (2018) 1016-1024.
22
23
- 24 [6] M.J. de Leon, Y. Li, N. Okamura, W.H. Tsui, L.A. Saint-Louis, L. Glodzik, R.S. Osorio, J. Fortea, T.
25
26 Butler, E. Pirraglia, S. Fossati, H.J. Kim, R.O. Carare, M. Nedergaard, H. Benveniste, H. Rusinek,
27
28 Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET, *J Nucl Med* 58(9)
29
30 (2017) 1471-1476.
31
32
- 33 [7] S. Jankeviciute, G. Psemeneckiene, R. Morkuniene, E. Grusauskiene, K. Petrikonis, D. Rastenyte, V.
34
35 Borutaite, Cerebrospinal fluids from Alzheimer's disease patients exhibit neurotoxic effects on neuronal
36
37 cell cultures, *Eur J Neurosci* 50(2) (2019) 1994-2006.
38
39
- 40 [8] X.B. Ding, X.X. Wang, D.H. Xia, H. Liu, H.Y. Tian, Y. Fu, Y.K. Chen, C. Qin, J.Q. Wang, Z. Xiang,
41
42 Z.X. Zhang, Q.C. Cao, W. Wang, J.Y. Li, E. Wu, B.S. Tang, M.M. Ma, J.F. Teng, X.J. Wang, Impaired
43
44 meningeal lymphatic drainage in patients with idiopathic Parkinson's disease, *Nat Med* 27(3) (2021) 411-
45
46 418.
47
48
- 49 [9] I. Parkinson Progression Marker, The Parkinson Progression Marker Initiative (PPMI), *Prog*
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Neurobiol 95(4) (2011) 629-35.

2
3 [10] J.M. Wardlaw, E.E. Smith, G.J. Biessels, C. Cordonnier, F. Fazekas, R. Frayne, R.I. Lindley, J.T.
4
5
6 O'Brien, F. Barkhof, O.R. Benavente, S.E. Black, C. Brayne, M. Breteler, H. Chabriat, C. Decarli, F.E.
7
8
9 de Leeuw, F. Doubal, M. Duering, N.C. Fox, S. Greenberg, V. Hachinski, I. Kilimann, V. Mok, R.
10
11
12 Oostenbrugge, L. Pantoni, O. Speck, B.C. Stephan, S. Teipel, A. Viswanathan, D. Werring, C. Chen, C.
13
14
15 Smith, M. van Buchem, B. Norrving, P.B. Gorelick, M. Dichgans, S.T.f.R.V.c.o. nEuroimaging,
16
17
18 Neuroimaging standards for research into small vessel disease and its contribution to ageing and
19
20
21 neurodegeneration, *Lancet Neurol* 12(8) (2013) 822-38.

22
23 [11] F. Fazekas, R. Kleinert, H. Offenbacher, R. Schmidt, G. Kleinert, F. Payer, H. Radner, H. Lechner,
24
25
26 Pathologic correlates of incidental MRI white matter signal hyperintensities, *Neurology* 43(9) (1993)
27
28
29 1683-9.

30
31 [12] F.N. Doubal, A.M. MacLulich, K.J. Ferguson, M.S. Dennis, J.M. Wardlaw, Enlarged perivascular
32
33
34 spaces on MRI are a feature of cerebral small vessel disease, *Stroke* 41(3) (2010) 450-4.

35
36 [13] G.M. Potter, F.N. Doubal, C.A. Jackson, F.M. Chappell, C.L. Sudlow, M.S. Dennis, J.M. Wardlaw,
37
38
39 Enlarged perivascular spaces and cerebral small vessel disease, *Int J Stroke* 10(3) (2015) 376-81.

40
41
42 [14] J.H. Kang, B. Mollenhauer, C.S. Coffey, J.B. Toledo, D. Weintraub, D.R. Galasko, D.J. Irwin, V.
43
44
45 Van Deerlin, A.S. Chen-Plotkin, C. Caspell-Garcia, T. Waligorska, P. Taylor, N. Shah, S. Pan, P. Zero,
46
47
48 M. Frasier, K. Marek, K. Kieburz, D. Jennings, C.M. Tanner, T. Simuni, A. Singleton, A.W. Toga, S.
49
50
51 Chowdhury, J.Q. Trojanowski, L.M. Shaw, I. Parkinson's Progression Marker, CSF biomarkers
52
53
54 associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers
55
56
57 Initiative study, *Acta Neuropathol* 131(6) (2016) 935-49.

58
59 [15] B. Mollenhauer, C.J. Caspell-Garcia, C.S. Coffey, P. Taylor, L.M. Shaw, J.Q. Trojanowski, A.
60
61
62

1 Singleton, M. Frasier, K. Marek, D. Galasko, I. Parkinson's Progression Marker, Longitudinal CSF
2
3 biomarkers in patients with early Parkinson disease and healthy controls, *Neurology* 89(19) (2017) 1959-
4
5
6 1969.

7
8
9 [16] A. Schrag, U.F. Siddiqui, Z. Anastasiou, D. Weintraub, J.M. Schott, Clinical variables and
10
11 biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease:
12
13 a cohort study, *Lancet Neurol* 16(1) (2017) 66-75.

14
15
16
17 [17] D.J. Irwin, J. Fedler, C.S. Coffey, C. Caspell-Garcia, J.H. Kang, T. Simuni, T. Foroud, A.W. Toga,
18
19 C.M. Tanner, K. Kieburtz, L.M. Chahine, A. Reimer, S. Hutten, D. Weintraub, B. Mollenhauer, D.R.
20
21 Galasko, A. Siderowf, K. Marek, J.Q. Trojanowski, L.M. Shaw, I. Parkinson's Progression Marker,
22
23 Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease, *Ann*
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

[18] Y.W. Park, N.Y. Shin, S.J. Chung, J. Kim, S.M. Lim, P.H. Lee, S.K. Lee, K.J. Ahn, Magnetic
Resonance Imaging-Visible Perivascular Spaces in Basal Ganglia Predict Cognitive Decline in
Parkinson's Disease, *Mov Disord* 34(11) (2019) 1672-1679.

[19] J.J. Iliff, M. Wang, D.M. Zeppenfeld, A. Venkataraman, B.A. Plog, Y. Liao, R. Deane, M.
Nedergaard, Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine
brain, *J Neurosci* 33(46) (2013) 18190-9.

[20] I. Riba-Llena, J. Jimenez-Balado, X. Castane, A. Girona, A. Lopez-Rueda, X. Mundet, C.I. Jarca, J.
Alvarez-Sabin, J. Montaner, P. Delgado, Arterial Stiffness Is Associated With Basal Ganglia Enlarged
Perivascular Spaces and Cerebral Small Vessel Disease Load, *Stroke* 49(5) (2018) 1279-1281.

[21] J.M. Wardlaw, H. Benveniste, M. Nedergaard, B.V. Zlokovic, H. Mestre, H. Lee, F.N. Doubal, R.
Brown, J. Ramirez, B.J. MacIntosh, A. Tannenbaum, L. Ballerini, R.L. Rungta, D. Boido, M. Sweeney,

1 A. Montagne, S. Charpak, A. Joutel, K.J. Smith, S.E. Black, D. colleagues from the Fondation Leducq
2
3 Transatlantic Network of Excellence on the Role of the Perivascular Space in Cerebral Small Vessel,
4
5 Perivascular spaces in the brain: anatomy, physiology and pathology, *Nat Rev Neurol* 16(3) (2020) 137-
6
7
8
9 153.

10
11 [22] E.K. Donahue, A. Murdos, M.W. Jakowec, N. Sheikh-Bahaei, A.W. Toga, G.M. Petzinger, F.
12
13 Sepehrband, Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's
14
15 Disease, *Mov Disord* 36(5) (2021) 1126-1136.
16
17

18
19 [23] Y. Li, Z. Zhu, J. Chen, M. Zhang, Y. Yang, P. Huang, Dilated Perivascular Space in the Midbrain
20
21 May Reflect Dopamine Neuronal Degeneration in Parkinson's Disease, *Front Aging Neurosci* 12 (2020)
22
23
24
25 161.
26

27
28 [24] B.L. Sun, L.H. Wang, T. Yang, J.Y. Sun, L.L. Mao, M.F. Yang, H. Yuan, R.A. Colvin, X.Y. Yang,
29
30 Lymphatic drainage system of the brain: A novel target for intervention of neurological diseases, *Prog*
31
32
33
34 *Neurobiol* 163-164 (2018) 118-143.
35

36
37 [25] A. Keable, K. Fenna, H.M. Yuen, D.A. Johnston, N.R. Smyth, C. Smith, R. Al-Shahi Salman, N.
38
39 Samarasekera, J.A. Nicoll, J. Attems, R.N. Kalaria, R.O. Weller, R.O. Carare, Deposition of amyloid
40
41 beta in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in
42
43 cerebral amyloid angiopathy, *Biochim Biophys Acta* 1862(5) (2016) 1037-46.
44
45

46
47 [26] M.A. Busche, B.T. Hyman, Synergy between amyloid-beta and tau in Alzheimer's disease, *Nat*
48
49
50
51 *Neurosci* 23(10) (2020) 1183-1193.
52

53
54 [27] L. Farotti, F. Paolini Paoletti, S. Simoni, L. Parnetti, Unraveling Pathophysiological Mechanisms of
55
56
57
58 Parkinson's Disease: Contribution of CSF Biomarkers, *Biomark Insights* 15 (2020) 1177271920964077.
59

60
61 [28] G. Banerjee, H.J. Kim, Z. Fox, H.R. Jager, D. Wilson, A. Charidimou, H.K. Na, D.L. Na, S.W. Seo,
62
63

1 D.J. Werring, MRI-visible perivascular space location is associated with Alzheimer's disease
2
3 independently of amyloid burden, *Brain* 140(4) (2017) 1107-1116.
4

5
6 [29] E.C. Gertje, D. van Westen, C. Panizo, N. Mattsson-Carlgen, O. Hansson, Association of Enlarged
7
8 Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease, *Neurology* 96(2) (2021)
9
10 e193-e202.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 **Figure legends**

2
3 **Figure 1. Correlation between CSF biomarkers and cognitive outcomes stratified by BG-PVS**

4
5
6 BG-PVS modified the effect of $A\beta_{42}/t\text{Tau}$ (A), $A\beta_{42}/p\text{Tau}$ (B), $A\beta_{42}$ (C) on cognitive outcome in
7
8
9 Parkinson's disease, as high BG-PVS group showed steeper decline in the MoCA score in relation to
10
11
12 CSF biomarkers at the 3-year follow-up.

13
14 Abbreviations: BG-PVS, basal-ganglia perivascular space; CSF, cerebrospinal fluid.

15
16
17 **Figure 2. Path analysis**

18
19
20 CSF $A\beta_{42}/t\text{Tau}$, but not $A\beta_{42}/p\text{Tau}$ or CSF $A\beta_{42}$ significantly mediated the effect of BG-PVS on
21
22
23 cognitive decline in patients with PD.

24
25 Abbreviations: BG-PVS, basal-ganglia perivascular space; CSF, cerebrospinal fluid; WMH, white
26
27
28 matter hyperintensity.

29
30
31
32
33
34 Supplementary figures:

35
36 **FIG. S1. Correlation between CSF biomarkers**

37
38
39 Abbreviations: CSF, cerebrospinal fluid.

40
41
42 **FIG. S2. Correlation between CSF biomarkers and cognitive decline stratified by the presence of**
43
44 **cardiovascular disease**

45
46
47 The presence of cardiovascular disease did not modify the effect of CSF biomarkers on cognitive
48
49
50 decline in patients with PD.

51
52
53 **FIG. S3. Path analysis for WMH, lacune, and CS-PVS**

54
55
56 CSF biomarkers did not mediate the effect of WMH, the presence of lacune or CS-PVS on cognitive
57
58
59 decline in PD.

Table 1. Demographic information between groups stratified by BG-PVS

	PD with low BG- PVS (N = 286)	PD with high BG- PVS (N = 55)	P value
<i>Demographic</i>			
Age (median, IQR, year)	60.7 (53.5–66.6)	71.1 (67.1–74.8)	<0.001
Gender (F/M)	100/186	15/40	0.269
<i>Disease profile</i>			
Disease duration (median, IQR, month)	4 (2–7)	6 (3–13)	0.066
MoCA Score (median, IQR)	28 (26–29)	27 (25–29)	0.222
Hoehn-Yahr staging (median, IQR)	2 (1–2)	2 (2–2)	0.001
MDS-UPDRS III total (median, IQR)	19 (14–26)	22 (16–27)	0.024
Tremor subscore (median, IQR)	5 (2–8)	6 (2–9)	0.117
Bradykinesia subscore (median, IQR)	11 (6–15)	14 (9–19)	0.008
Axial subscore (median, IQR)	4 (2–5)	4 (3–7)	0.008
Rigidity subscore (median, IQR)	4 (2–6)	5 (3–9)	0.031
State Trait Anxiety Score (median, IQR)	94 (89–98)	94 (88–97)	0.500
Geriatric Depression Scale (median, IQR)	5 (5–6)	5 (4–6)	0.280
<i>CSF biomarkers</i>			
CSF α -synuclein (median, IQR, pg/ml)	1351.3 (1029.3– 1718.0)	1528.8 (1164.3– 2086.0)	0.016
CSF A β ₄₂ (median, IQR, pg/mL)	848.6 (615.1– 1119.0)	822.2 (627.9– 1050.5)	0.860

CSF pTau (median, IQR, pg/mL)	13.0 (10.9–16.7)	15.4 (12.4–21.4)	0.001
CSF tTau (median, IQR, pg/mL)	152.6 (124.0–	186.4 (147.2–	<0.001
	192.6)	237.7)	
CSF A β ₄₂ /tTau	5.81 (4.69–6.69)	4.88 (3.71–6.01)	0.002
CSF A β ₄₂ /pTau	69.4 (57.4–80.3)	61.1 (42.7–75.7)	0.002
<i>DAT striatal binding ratios</i>			
Mean caudate uptake (median, IQR)	2.02 (1.67–2.37)	1.88 (1.54–2.21)	0.155
Mean putamen uptake (median, IQR)	1.79 (1.48–2.18)	1.77 (1.34–2.08)	0.270
Caudate asymmetry (median, IQR)	1.19 (1.10–1.31)	1.17 (1.07–1.27)	0.216
Putamen asymmetry (median, IQR)	1.45 (1.19–1.76)	1.39 (1.17–1.73)	0.484
<i>Small vessel disease profile</i>			
WMH Fazekas score (median, IQR)	2 (1–2)	3 (2–4)	<0.001
The presence of lacune (N, %)	145 (50.7%)	45 (81.8%)	<0.001
Cardiovascular diseases (N, %)	224 (52.1%)	57 (77.0%)	<0.001
Cerebrovascular diseases (N, %) ^a	2 (0.5%)	2 (2.7%)	0.195
<i>Genetic profile</i>			
Presence of APOE ϵ 4 allele (N, %)	68 (23.8%)	13 (23.6)	0.982
<i>Cognition at 3-year follow-up</i>			
Change in MoCA score (median, IQR)	0 (-2–1)	-2 (-5–0.25)	0.004
Cognitive impairment (N, %)	46 (18.9)	22 (48.9%)	<0.001

^aCorrection for continuity was adapted for inadequate event.

1 Abbreviations: CSF, cerebrospinal fluid; DAT, dopaminergic transporter; IQR, interquartile range;

2
3 MDS-UPDRS III, Movement Disorder Society Unified Parkinson's Disease Rating Score part III;

4
5
6 MoCA, Montreal Cognitive Assessment.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 2. Linear mixed model for interactive effect of CSF markers and BG-PVS on cognitive outcomes

	MoCA score at 3-year follow-up				Change in MoCA from baseline to 3-year follow-up			
	Model without interaction		Model with interaction		Model without interaction		Model with interaction	
	Coefficient	P value	Coefficient	P value	Coefficient	P value	Coefficient	P value
Model 1								
Baseline A β ₄₂ /tTau	0.385 (0.154–0.617)	0.001	1.087 (0.650–1.524)	<0.001	0.388 (0.156–0.619)	0.001	1.086 (0.649–1.523)	<0.001
BG-PVS \geq 2	REF		REF		REF		REF	
BG-PVS<2	1.302 (0.271–2.334)	0.014	6.364 (3.515–9.214)	<0.001	1.317 (0.285–2.349)	0.013	6.357 (3.507–9.207)	<0.001
A β ₄₂ /tTau*BG-PVS	/		-0.953 (-1.460–-0.445)	<0.001	/		-0.949 (-1.456–-0.441)	<0.001
Interaction								
AIC	823.4		811.4		823.2		811.3	
Model 2								
Baseline A β ₄₂ /pTau	0.031 (0.011–0.050)	0.002	0.095 (0.059–0.131)	<0.001	0.031 (0.011–0.050)	0.002	0.095 (0.059–0.131)	<0.001


16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


BG-PVS \geq 2	REF		REF		REF		REF	
BG-PVS<2	1.364 (0.282–2.445)	0.014	7.040 (4.170–9.909)	<0.001	1.387 (0.305–2.468)	0.013	7.057 (4.186–9.927)	<0.001
A β ₄₂ /pTau*BG-PVS interaction	/		-0.088 (-0.130–0.046)	<0.001	/		-0.088 (-0.130–0.046)	<0.001
AIC	782.6		772.5		782.4		772.3	
<hr/>								
Model 3								
Baseline A β ₄₂	0.001 (0–0.002)	0.033	0.003 (0.001–0.005)	0.003	0.001 (0–0.002)	0.034	0.003 (0.001–0.005)	0.003
BG-PVS \geq 2	REF		REF		REF		REF	
BG-PVS<2	1.286 (0.253–2.318)	0.015	3.328 (1.224–5.432)	0.002	1.299 (0.266–2.331)	0.014	3.326 (1.221–5.430)	0.002
A β ₄₂ *BG-PVS interaction	/		-0.002 (-0.004–0)	0.029	/		-0.002 (-0.004–0)	0.030
AIC	867.6		874.8		867.9		875.2	


CSF biomarkers (A β ₄₂, A β ₄₂/tTau, A β ₄₂/pTau), BG-PVS and their interaction were fixed effect; age, baseline MoCA score, axial subscore of MDS-UPDRS III, RBDSQ, UPSIT, and putamen asymmetry, WMH Fazekas score, the presence of lacune, past history cardiovascular diseases were set as random effect.; Abbreviations: AIC, Akaike

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

information criterion; BG-PVS, basal ganglia perivascular space; REF, reference.








[Click here to access/download](#)

Optional E-Only Supplementary Files

Fig. S1.tif






Click here to access/download

Optional E-Only Supplementary Files

Fig. S2.tif






[Click here to access/download](#)

Optional E-Only Supplementary Files


Fig. S3.tif





[Click here to access/download](#)

Optional E-Only Supplementary Files
supplementary result.docx





[Click here to access/download](#)

Optional E-Only Supplementary Files
Supplementary tables_R2_clean.docx

